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“Our revels now are ended. These our actors, 
As I foretold you, were all spirits, and 
Are melted into air, into thin air: 
And like the baseless fabric of this vision, 
The cloud-capp'd tow'rs, the gorgeous palaces, 
The solemn temples, the great globe itself, 
Yea, all which it inherit, shall dissolve, 
And, like this insubstantial pageant faded, 
Leave not a rack behind. We are such stuff 
As dreams are made on; and our little life 
Is rounded with a sleep.” 
 
The Tempest, William Shakespeare 
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 Abstract 
 
Infection, trauma or tumors can generate critical bone defects in which the regeneration is 
compromised, thus necessitating the development of suitable repair strategies. Conventional tissue-
engineered approaches proposed the use of a three-dimensional (3D) scaffold that supports cell 
growth and differentiation, in which the seeded progenitor cells can secrete an extra-cellular matrix 
(ECM) coating the material. The resulting bone graft can then be implanted in the patient in an 
autologous set-up.  However, a more attractive paradigm consists in the removal of the cellular 
fraction from the graft prior to its implantation in order to avoid immuno-matching requirements, 
toward a universal exploitation of the graft. This conceptual strategy relies on the capacity of 
osteoinductive signals embedded in the ECM to instruct endogenous cells toward bone repair.  
The success of this approach requires a standard cell source capable of secreting an osteo-inductive 
ECM, but also the development of a suitable decellularization protocol that can lead to both an 
efficient cell removal from the graft and the preservation of ECM properties. 
In this thesis, I report the combined development of a standardized cell source and an apoptotic-
based decellularization strategy, through the generation of a death-inducible human Mesenchymal 
Stromal Cell (hMSC) line. This cell line was shown to retain typical hMSC properties while 
continuously proliferating without signs of tumorigenicity, and being efficiently inducible toward 
apoptosis. Using this unlimited and well-characterized cellular tool, we successfully generated 
acellular ECM-coated graft within a 3D perfusion bioreactor. In particular, the induction of cell 
apoptosis was used as a decellularization procedure leading to the better preservation of key ECM 
components, as compared to the conventional approach. 
Overall, by relying on both a novel cell source and a new decellularization approach, the developed 
protocol may lead to the development of a bone repair treatment with superior standardization and 
possibly cost-effectiveness as compared to current strategies.  
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Chapter 1 
 
 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 Bone 
1.1 Structure and function 
Bone is a rigid but porous organ involved in structural, metabolic but also physiological processes in 
the body. Together with its living compartment, the particular structure of bones leads to a unique 
fulfillment of functions.  
Bone extracellular matrix (ECM) is of mixed composition, including an inorganic (calcium 
hydroxyapatite crystals) and an organic part mainly composed of collagen type 1, but also of key 
proteins such as osteocalcin, osteonectin, bone sialo protein and osteopontin (legeros1). The bone 
ECM displays a relatively low elasticity but essential rigidity that confers the strong robustness to the 
structure. The solidity of bones has to be correlated with their mechanical function, bones serving 
both as template for body support and as natural protective barrier. In addition, together with the 
muscles they participate to the body movement.  
The bone matrix is a very dynamic environment orchestrated by its living fraction. Bone cells include 
osteoblast, osteoclast and osteocyte that are respectively responsible for bone mineralization, 
resorption and tissue homeostasis (2). This bone remodeling process is essential as bones serve as 
ions reservoir, balancing the body mineral content (e.g. Ca
2+
 turnover).  
Bones are organized in two distinctive structures: the peripheral cortical bone and the internal 
trabecular bone. The cortical part is compact whereas the trabecular one is spongy and surrounded 
by the marrow compartment that fills the cavity (figure 1). The bone marrow is a tissue mainly 
composed of blood, fat and fibrotic cells. Importantly, long bones are the hematopoiesis center, a 
process giving birth to the entire white (myeloid and lymphoid cells) and red cells (erythrocytes and 
megakaryocytes) population.  
  
Figure 1. Structure of bone. 
(http://www.mhhe.com/biosci/esp/2001_gbio/folder_structure/an/m5/s2/index.htm) 
 
1.2 Bone healing & clinical need 
Bone is an important organ and its integrity is crucial for the proper protection, locomotion and 
functioning of the body. Upon trauma, bones can naturally heal by themselves notably through the 
presence of osteoprogenitors driving the restoration of the tissue (3) with identical physical 
properties than the original one.  However, infections, tumors or accidents can result in bone defects 
with a compromised regeneration. Healing problems can be associated with a poorly vascularised 
environment, a distance over 2 cm between bone ends or the non-stabilization of the fracture-
healing site (4). Overall, with 2.2 million bone grafts are performed yearly (5), the healing of bone 
represents a major clinical concern making the development of bone regeneration therapy a 
necessity. 
 
1.3 Existing bone repair strategies 
 
The repair of bone defects can be treated via a variety of clinical approaches. The current clinical gold 
standard consists in the transplantation of autologous bone graft (e.g. extracted from the iliac crest 
or the fibula) used as osteogenic substitute. Despite the suitability of this approach, it is associated 
with intrinsic harvest site morbidity and the limited availability of the material (6, 7). The use of 
 allograft or xenografts can be considered as potential alternatives but their immunogenicity, 
combined with the risk of disease transmission still raises concerns (8, 9).  
Synthetic scaffolds (e.g. titanium, ceramic) allow avoiding immunogenic issues and can successfully 
provide a structural template. Nevertheless, these bone substitution materials are not necessarily 
osteoinductive/osteogenic enough and problems in regards to their biocompatibility and/or 
biodegradability may arise from (10).  
Another possibility relies on the injection of growth factors such as human bone morphogenetic 
proteins (BMPs), use as strong inducer of osteogenesis. Despite a demonstrated bone formation 
efficiency, the required high doses are associated with aberrant bone formation (11, 12), 
neurotoxicity and cancer development, leading to a difficult tuning for safe local application (12). 
Taken together, the aforementioned strategies suffer from clear limitations and may not be sufficient 
to promote a fast, complete and stable bone repair. 
  
1.4 Tissue engineering approaches 
Progress made in the fields of stem cell biology and bioengineering lead to the development of in 
vitro engineered tissue. The approach consists in the use of a synthetic or natural three-dimensional 
(3D) scaffold that supports cell growth and differentiation, in which the patient seeded progenitor 
cells can secrete an ECM coating the material (figure 2A). The resulting bone graft contains both 
living osteoprogenitors that participate to the new bone formation following implantation, but also 
osteoinductive signals embedded in the ECM that can instruct endogenous cells toward bone repair 
(13-15). Limits arising from this approach come from the cell source that displays an intrinsic donor-
to donor variation and is of limited supply. Moreover, this strategy only leads to the autologous 
exploitation of the generated bone substitute. 
Therefore, a more attractive paradigm has been proposed through the in vitro generation of bone 
grafts followed by their decellularization prior to implantation into a defect site (figure 2B). The 
hypothesis lying behind this conceptual approach is that the remaining ECM can induce bone 
regeneration despite the cellular depletion, through the preservation of key instructive factors 
 entrapped in the tissue. Importantly, the resulting acellular ECM-coated material may not be 
immunogenic as the ECM proteins are well conserved even across species (16). The absence of 
immuno-matching requirements may lead to the generation of universal, non-patient specific graft.  
 
 
Figure 2. Tissue Engineering approaches. Starting from a biopsy, a graft can be engineered in vitro and re-
implanted into the defect site (A). An alternative concept (B) aims at decellularizing the generated graft prior to 
implantation. The acellular graft can then be implanted in any patients to promote an efficient bone repair. 
 
From a clinical standpoint, decellularized ECM with an intrinsic capacity to induce bone formation 
would be highly attractive. In particular, it would avoid autologous cell processing, which is time 
consuming and costly, but also lead to a standardized product as by-passing inter-individual 
variability that severely limits current clinical applications. Overall, this strategy may facilitate the 
clinical translation of the produced graft, as more cost-effective, feasible and possibly effective than 
conventional tissue engineering strategies. 
 
2 Critical components of conventional engineered bone substitutes 
The success of tissue engineering based strategies may highly depend on key parameters such as the 
cell source, the scaffolding material, the culture conditions, the decellularization strategy, but also of 
the vascularization post-implantation, providing direct evidence of successful engraftment.  
 2.1 Cell source 
The engineering of biological bone graft involved the seeding of osteogenic cells on 3D scaffolding 
material. Different cell sources have been already used for the generation of osteogenic graft (figure 
3) (17), such as adipose (18), muscle (19), cord blood (20), and more recently embryonic (21) or 
induced pluripotent stem cells (22). Nevertheless, bone marrow-derived mesenchymal stromal cells 
(BMSC) remains the most common cell source for tissue engineering, from both an experimental and 
clinical point of view (23). 
BMSC are an easily accessible cell source that can be isolated from bone-marrow aspirate through a 
minimally invasive procedure. BMSC are defined as a subset of non-hematopoietic, multipotent and 
self-renewing stromal cells (24).  Those cells are isolated on the basis of their adherence and colony-
forming unit-fibroblasts (CFU-F) capacity following whole bone-marrow plating. BMSC are currently 
described as positive for the CD105, CD73, CD90 markers and negative for CD34, CD14/11b, 
CD79a/19 and HLA-DR surface molecules (Mesenchymal and Tissue Stem Cell Committee of the 
International Society for Cellular Therapy). However, a complete panel of surface markers defining 
these cells still needs to be identified.   
BMSC are promising candidates for regenerative purposes because of their demonstrated multi-
lineage differentiation capacity. BMSC have been shown to be able to differentiate into the three 
main lineages of mesenchymal tissue, namely bone, cartilage and adipose (25). BMSC are also 
described as being capable to migrate and engraft at injury sites (26) triggering immuno-modulation 
properties and eventually generating a local immuno-suppressive effect (27). This can potentially 
lead to an allogeneic exploitation of these cells (28-30), as currently investigated in the context of 
bone marrow transplant (31). 
 
 Figure 3. Cell source for bone tissue engineering. BMSC; Bone marrow-derived mesenchymal stromal cells, 
ADSC; Adipose-derived mesenchymal stromal cells, MDSC; Muscle-derived mesenchymal stromal cells, UCMSC; 
Umbilical cord-derived mesenchymal stromal cells, AFSC; Amniotic fluid-derived mesenchymal stromal cells, 
ESC; Embryonic stem cells, iPS; induced pluripotent stem cells. Adapted from (17). 
 
Nevertheless, the inherent problems common to all cell sources -including BMSC, arise from the 
limited availability and the variability among donors (32). In fact, the low amount of osteoprogenitor 
cells isolated from a biopsy typically mandates an in vitro expansion phase. In particular, the 
frequency of BMSC within bone marrow aspirates does not exceed 0.001 to 0.1% of nucleated cells 
and their amplification is limited by the replicative senescence phenomenon occurring in in vitro 
culture after a certain number of population doublings (PD) (33, 34). Moreover, the differentiation 
potential of BMSC -and subsequently their capacity to generate a mature tissue, is reduced along 
with their population doubling level (32, 35). So far, no marker of BMSC functionality has been 
identified making difficult the assessment of the cell-source quality thus complicating successful 
therapeutic prognosis. 
Overall, the donor-to-donor variations combined with the small amount of available BMSC and their 
limited life-span makes both their potential use difficult and the development of standardized 
procedures unlikely. Toward this perspective, a suitable cell source for the standard generation of 
osteogenic graft should maintain the basic properties of BMSC over time, while being of substantial 
availability.  
 
 
 
 
 2.2 Scaffolding material  
Scaffolds aim at providing a 3D structure that support cell attachment, proliferation and 
differentiation. The material offers a template that seeded cells may be able to remodel while 
depositing an ECM, thus mimicking the reconstruction of their natural environment.  
Two types of scaffold can be distinguished whether they are from natural origin (e.g. decellularized 
bone, collagen-based) or purely synthetic (e.g. titanium, polycaprolactone). It is generally recognized 
that no ideal scaffold can be defined, even for a specific tissue.  As for bone, the diverse roles carried 
on by a tissue make unlikely the regeneration and subsequent restoration of the ensued functions by 
the use of a unique material (36). Nevertheless, it is possible to identify and consider key 
characteristics such as the composition, architecture, structural mechanics, surface properties, or 
biocompatibility/degradability, in order to envision a suitable material for a specific regeneration 
purpose (36).  
In the context of bone tissue engineering, candidate materials should display key properties such as 
(i) biocompatibility and biodegradability, (ii) a certain rigidity and porosity (thus resembling the 
natural bone tissue), (iii) and osteoconductivity, for an optimal integration of the graft (37). 
Importantly, the presence of a mineral component in the scaffold may be needed, as shown to be 
notably required for an ectopic in vivo bone formation (38).  
In this regard, ceramic materials appear extremely promising for bone repair. Ceramic scaffolds can 
be obtained from decellularized bone (biologic origin), or derived from a manufacturing process 
(synthetic origin). Synthetic ceramics can be tailored to achieve both a porosity resembling the one 
of natural bone tissue, as well as an adapted shape perfectly filling the defect site. Ceramics are 
composed of calcium-phosphate/hydroxyapatite crystals that display a similar size and morphology 
to that of bone apatite. This results in equivalent biodegradability (39), bioactivity, osteoconductivity 
(supporting bone ingrowth) and osteoinductivity (inducing bone formation) than bone tissue. For this 
reasons, ceramics are already used as dental implant (40, 41) and in orthopedic surgery (42, 43). 
Several studies also report the successful combination of osteoprogenitors and ceramic-based 
scaffolds for the generation of bone graft (44, 45).  
  
Table 1. Overview of scaffold used in regenerative medicine (46-49). 
 
2.3 Culture conditions 
Following the choice of suitable cell source and scaffolding material, the culture conditions need to 
be defined as playing an important role in the development of an osteogenic graft.  
The medium composition and associated growth factors allow guiding cells toward proliferation and 
differentiation, as well as promoting the deposition of a rich ECM coating the material. Specific 
culture conditions have been identified to direct the osteogenic differentiation of cells in vitro (50). 
 Other parameters such as the temperature or the oxygen supply are also of importance as 
influencing cell differentiation (51).  
Culture systems have been also described as playing a central role for the generation of appropriate 
osteogenic grafts. Importantly, over the last years 3D culture within bioreactor system has emerged 
as alternative to classic 2D, monolayer culture. The development of such device, and in particular 
perfusion-based devices, allowed for a better monitoring of the culture conditions (52), while 
introducing other tuneable variable such as flow rate (mechanical stimulation), which also offers the 
possibility of a dynamic cell seeding (53, 54). In particular, the strict control of the culture parameters 
conferred by these devices is in line with the development of clinical-grade conditions, toward the 
clinical translation of engineered tissue (52). 
Initially developed to better mimic the physiologic environment of cells (55), leading to a better 
preservation of their intrinsic differentiation potential (56), bioreactor systems also allow the 
formation of more homogeneous tissue (57). The perfusion confers the possibility to provide 
nutrients supply throughout the graft while removing the toxic cellular waste. Taken together, this 
allows the development of scaled-up tissue engineered constructs of homogeneous quality, while 
avoiding the formation of a necrotic core typically appearing in grafts of critical size. 
 
2.4 Vascularization 
The metabolic waste removal as well as the supply of oxygen, nutrients and factors is of high 
importance upon transplantation in order to either allow the survival of the implanted living fraction, 
or the rapid graft colonization with osteoprogenitors in the case of an acellular graft. Moreover, a 
proper bone remodelling requires an active process of angiogenesis that supplies the necessary 
growth factors and stem cells (58). Thus, from the rapid development/recruitment of a vasculature 
may depend the successful and stable integration of the implanted graft.  
Hence, vascularization is a central issue in tissue engineering and its promotion may be needed. 
Current strategies notably proposed the delivery of angiogenic signals (59) such as Vascular-
Endothelial Growth-Factor α (VEGFα), Fibroblast-Growth-Factors (FGFs) or Platelet-Derived-Growth 
 Factor (PDGF). VEGFα is a potent contributor of angiogenesis, promoting the formation of capillaries, 
by stimulating the survival, proliferation and migration of endothelial cells (60). FGFs (type 1 and 2) 
can stimulate the proliferation and differentiation of both endothelial and smooth muscle cells. 
Instead, PDGF only allow the recruitment of smooth muscle cells to form pre-capillary sphincters, 
allowing for blood vessel contraction and relaxation (61). Nevertheless, the delivery of growth factors 
to enhance the vascular network establishment required defined doses and a controlled kinetic of 
release to achieve a safe therapeutic effect. An improper strategy may indeed result either in an 
inefficient promotion of vascularization or in the formation of aberrant vessels/angiomas (62). In the 
context of engineered bone tissue, osteoprogenitors are known to secrete angiogenic factors 
including VEGF (63), from which a certain amount is entrapped in the deposited ECM (64). Thus, both 
implanted cells and/or the ECM coating the material are expected to participate in the recruitment of 
host vessels after implantation. 
The co-culture of osteoprogenitors with an endothelial fraction is an alternative strategy. Those 
vasculogenic cells are expected to form a capillary network (in vitro or in vivo) (18, 65) that can 
connect with host vessels, leading to improved survival of the grafted cells. Nevertheless, the use of 
an endothelial progenitors source suffers from a lack of abundance in biopsy and their isolation is 
considered clinically unsuitable as complex, multi-tasking and costly (38). 
 
3 Generation of acellular osteogenic grafts 
3.1 State-of-the-art living graft  
(i) Osteogenicity assessment 
Tissue engineering approaches for bone repair consist in the combination of stem cells and an 
appropriate scaffold, in order to generate an osteogenic material. The best assessment of the 
osteogenic potential of a human graft is performed through its ectopic (e.g. subcutaneously) or 
orthotopic (e.g. cranial defect) implantation into immunodeficient animals (66).  
Ectopic implantation sites are the most stringent condition as no bone can naturally form in this 
environment. As a consequence, the eventual induced bone formation can only be attributed to the 
 cells and/or signals arising from the implant. Orthotopic models are more clinically relevant allowing 
assessing the intrinsic osteogenicity of an implant. However, in this model the induced bone 
formation is often the result of both host and grafted cells, making the evaluation of the graft 
participation in the repair difficult. Importantly, orthotopic site also allows assessing the 
osteoconductivity of the graft by visualizing the possible construct integration within the host bone.  
In both ectopic and orthotopic models, the use of immuno-compromised animals however appears 
to be a limitation. Beyond the interspecies differences in bone formation, these models might also be 
problematic in the sense that they do not reflect the inflammatory mechanisms that naturally occur 
in immunocompetent organism (67). 
(ii) State-of-the-art 
The generation of in vitro tissue was developed in order to obtain graft with enhanced osteogenic 
properties. The capacity of engineered tissue to promote bone formation was observed in both 
ectopic (68-70) and orthotopic models (71, 72) using BMSC differentiated on 3D scaffold. 
Interestingly, most of the successful study involved the use of ceramic materials, promoting the 
osteogenic differentiation of seeded cells and also providing the necessary mineral substrate for the 
formation of bone. In comparison, inert scaffolds without the supply of strong BMPs doses typically 
fail in generating mature bone tissue at an ectopic implantation site (38).  
The relative success of the cell-based tissue engineering has to be tempered by the limited 
standardization of the graft quality. As the bone formation mainly results from the transplant cells, 
this strategy is highly dependent of the cell source quality, limiting a full exploitation of this 
approach. Moreover, despite successful study conducted in large animals, few of them led to clinical 
translation.  One of the key factor involved the survival of the cells following implantation (73). In 
large bone defect, the rapid vascularization is a requirement to allow implanted cells to form bone. 
An alternative strategy should not only rely on the cell compartment to induce bone formation and 
provide the necessary osteogenic and angiogenic factors for a rapid engraftment.  
The generation of decellularized grafts represents a promising alternative, as aiming at inducing bone 
formation through the secreted ECM and embedded factors. Importantly, the removal of the cellular 
 compartment prior to implantation may also allow the allogeneic exploitation of the tissue, as off-
the-shelf product. Nevertheless, the success of this strategy entirely relies on the deposition of an 
osteoinductive ECM by the cultured cells, and its preservation upon decellularization procedure. 
 
3.2 The extracellular matrix 
The ECM is a combination of structural and functional proteins, proteoglycans, lipids and crystals that 
has a unique composition and physical properties for every tissue and organ in the body. Acting as a 
reservoir for morphogens while providing mechanical support for resident cells, ECM participates in 
cell communication as well as in defining the shape and stability of tissues (74). ECM cues have been 
demonstrated to specifically promote cell recruitment, adhesion, migration, proliferation and 
differentiation in a way that reflects the functional needs and biological identity of tissues (75). In 
bone, residing cells are known to secrete key factors that serve as inflammatory mediators, matrix-
degrading enzymes as well as osteoinductive signals (1). The suitable presentation of those 
embedded factors may induce instructive processes such as bone-resorption/formation, 
angiogenesis, or immune cell recruitment.  
 
3.3 Decellularized ECM in regenerative medicine 
The concept of using decellularized ECM to induce repair relies on the hypothesis that its instructive 
elements may retain at least in part their functionality even in the absence of the living cellular 
component. Based on this rationale, decellularized ECM has received increased attention in the field 
of regenerative medicine as an off-the-shelf and immune-compatible alternative to living grafts for 
tissue and organ repair. Decellularized ECM is expected to induce regenerative processes through the 
physiological presentation of different cocktails of regulatory molecules in a mechanically suitable 
environment. 
The instructive ECM-coated scaffold material could be activated by living cells prior to implantation, 
with the assumption that ECM is capable of directing the differentiation fate of the seeded cells (15, 
76, 77). However, in a more attractive paradigm, the decellularized ECM could be directly used to 
 instruct resident cells towards endogenous tissue repair. The described concept has received 
convincing proof-of-principle evidences from epithelial (78), musculoskeletal (79), vascular (80), 
myocardial (81), pulmonary (82), renal (83) and pancreatic tissue engineering (84). 
Starting from decellularized native bone as a prototype ECM graft [13], bone tissue engineering has 
evolved toward the generation of cell-laid coated material.  The instructive capacity of those 
engineered and subsequently decellularized ECM was already demonstrated. ECM deposited in vitro 
by BMSC has been shown to support cell proliferation, prevent spontaneous differentiation and 
enhance the osteogenic capacity of freshly reseeded BMSCs (85, 86). The osteogenicity of this 
acellular ECM graft was also demonstrated in vitro (87), as efficiently fostering the osteoblastic 
differentiation of BMSC.  
Additional studies report the successful formation of bone by using decellularized ECM combined 
with hydroxyapatite scaffold, implanted in a rodent critical-sized cranial defect (88, 89). Using 
bioreactors, the osteogenic performance of a polymeric scaffold was enhanced by the ECM 
deposited by BMSC. Nevertheless, those constructs were shown not to be capable to induce bone 
formation when implanted in an ectopic environment. Moreover, the reported bone formation 
induced by decellularized ECM graft in an orthotopic model was shown to be very limited and the 
created defect could not be filled despite a substantial in vivo period. 
Taken together, if the use of decellularized ECM as osteo-inductive material was shown to be a 
promising strategy, the improvement of the final osteoinductivity appears to be essential. In 
particular, the use of a cell source with standard properties may be a requirement, as well as the 
choice of a suitable decellularization technique. 
 
3.4 Existing decellularization strategies 
Decellularization protocols aim at removing all cellular material without adversely affecting the 
composition, mechanical integrity and eventual biological activity of the remaining ECM (90). The 
effective removal of antigenic epitopes associated with cell membranes and intracellular 
components of tissues is necessary to minimize or avoid an adverse immunologic response by 
 allogeneic and xenogeneic recipients of the ECM scaffold material. For this purpose, a variety of 
methods have been developed, which can mainly be divided into chemical, biological or physical 
treatments (table 2).  
Chemical-based procedures rely on the use of acids and bases, hypertonic/hypotonic solutions or 
detergents (e.g. Triton-X, Sodium dodecyl sulfate) while biological ones involved the use of enzymes 
such as trypsin or nucleases. Instead, typical physical treatments consist in temperature variations 
(freeze & thaw cycles) or mechanical pressure. Protocols described in literature tend to combine 
several of these principal methods in order to increase the efficiency of decellularization and at the 
same time reduce damage to the ECM by using less destructive conditions.  
All of the above mentioned methods can reach variable degrees of decellularization efficiency, but all 
fail in preserving the integrity of the ECM, making the development of alternative decellularization 
strategy a necessity. A standard decellularization method preserving both the structure and 
composition of an in vitro generated graft may support a regenerative response. In fact, the 
maintenance of the integrity of the ECM following decellularization is expected to support a more 
predictable, reproducible and effective clinical use of the resulting material through the preservation 
of the osteoinductive potential of the graft.  
 
  
Table 2. Overview of existing decellularization procedures (75, 91-96). 
  
 
4 Aims of the thesis 
4.1 General aims 
The use of engineered decellularized tissue appears as a promising strategy to promote bone repair, 
offering the possibility to induce a repair without immuno-matching requirement. Nevertheless, clear 
limitations have been identified. First, the development of a cell source displaying stable properties 
and substantial availability appears to be essential for the generation of standardized ECM-coated 
material. Moreover, the preservation of the ECM integrity is necessary for eliciting a regenerative 
response. As existing decellularization protocols vary in their cell removal efficiency and do not allow 
for a controlled preservation of the structural, biochemical and/or biomechanical features of the 
engineered tissues, the development of an alternative strategy is a necessity.  
 My thesis proposes the combined development of (i) a suitable cell source and (ii) a decellularization 
strategy for the generation of tissue engineered bone graft. The successful association of these key 
components of the tissue engineering paradigm is expected to lead to (iii) the standardized 
generation of ECM-coated materials with enhanced properties.  
 
4.2 Chapters content description 
The experimental work constitutes three chapters, in the form of scientific publications.  
Chapter 2 describes the generation of the first immortalized but death-inducible cell line, aiming at 
solving cell source availability and standardization issues. For this purpose, a human Mesenchymal 
Stromal Cell (hMSC) line inducible toward apoptosis was generated, through the implementation of a 
human telomerase gene and a pre-established inducible suicide device (Bourgine et al., Stem Cell 
Research, Re-Submitted). The cell line represents a relevant tool for bone tissue engineering 
applications as displaying a continuous growth while retaining stable differentiation properties. In 
particular, the integrated suicide system leads to an increase of safety margins, allowing for a 
temporally controlled survival of cells. 
 
Chapter 3 is a description of a novel decellularization procedure for the generation of acellular tissue 
with preserved properties. It reports the possibility to decellularize native or engineered tissue by 
activation of programmed cell death. In particular, the concept of apoptotic-driven decellularization 
has been explored in the context of bone tissue engineering for the generation of acellular grafts 
with preserved properties (97). 
 
Finally, chapter 4 reports the successful combination of the generated cell line and the apoptotic-
based decellularization procedure for the generation of ECM-coated constructs. The activation of the 
suicide system integrated in the cell line serves as decellularization method. Using a perfusion-based 
3D culture system, the engineered cell line was shown to adhere, proliferate, differentiate and to 
deposit an ECM when seeded on ceramic scaffold. The resulting generated constructs were directly 
 and efficiently decellularized by convection of the apoptotic-inducer within the perfusion bioreactor 
system, leading to the successful generation of decellularized ECM-coated constructs. Importantly, 
the decellularization by apoptosis was demonstrated to better preserve the matrix integrity as 
compared to the conventional Freeze & Thaw method (Bourgine et al., manuscript in preparation).  
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 Abstract 
The hTERT-immortalization of human bone marrow-derived Mesenchymal Stromal Cells (hMSCs) 
was proposed to address availability/standardization issues for experimental or clinical studies, but 
raised concerns due to possible uncontrolled growth or malignant cell transformation. 
Here we report a method to generate a hMSCs line with controlled survival, through the 
implementation of a pre-established suicide system (inducible caspase 9, iCasp9) in hTERT-
transduced hMSCs.  
Primary hMSCs were successfully immortalized (>280PD) and further transduced with the iCasp9 
device. A clone was selected and shown to maintain typical properties of primary hMSCs, including 
phenotype, differentiation and immunomodulation capacities. The successive transductions did not 
induce tumorigenic transformation, as assessed by analysis of cell cycle regulators and in vivo 
luciferase-based cell tracking. Cells could be efficiently induced toward apoptosis (>95%), even upon 
differentiation.  
By combining the opposite concepts of `induced-life’ and `inducible-death’, we generated a hMSCs 
line with defined properties and allowing for temporally controlled survival. The cell line represents a 
relevant tool for medical discovery in regenerative medicine and a potential means to address 
availability, standardization and safety requirements in cell & gene therapy. The concept of a hTERT-
iCasp9 combination, here explored in the context of hMSCs, could be extended to other types of 
progenitor/stem cells. 
 
 
 
 
 
 
 
 Introduction 
Human bone marrow-derived Mesenchymal Stem/Stromal Cells (hMSCs) are widely investigated in 
regenerative medicine due to their multilineage differentiation capacity (Pittenger, Mackay, Beck, 
Jaiswal, Douglas, Mosca, Moorman, Simonetti, Craig, and Marshak, 1999), immunomodulatory 
properties (Nauta and Fibbe, 2007), as well as their ability to migrate and deliver regulatory factors at 
injured sites or within tumour stroma (Kidd, Spaeth, Dembinski, Dietrich, Watson, Klopp, Battula, 
Weil, Andreeff, and Marini, 2009). Despite the large scientific interest and broad range of potential 
therapeutic applications, the coherent pre-clinical and clinical use of hMSCs is challenged by several 
critical issues, including the limited availability and the variability among different donors (Phinney, 
Kopen, Righter, Webster, Tremain, and Prockop, 1999).  
The low amount of hMSCs in bone marrow aspirates (0.001 to 0.1% of nucleated cells) typically 
necessitates an in vitro expansion phase prior to use. The phase of amplification is limited by the 
replicative senescence phenomenon occurring under in vitro culture conditions, typically after 30 to 40 
population doublings (PD) (Stenderup, Justesen, Clausen, and Kassem, 2003). Along with serial 
passages, the differentiation potential of hMSCs is reduced and functional changes have been reported 
(Minguell, Erices, and Conget, 2001;Siddappa, Licht, van, and de, 2007a). The need for extensive 
hMSCs expansion, combined with their short life-span, is aggravated by the high variability among 
preparations from different donors, even if in the same age range (Siddappa, Licht, van, and de, 
2007b).  
To overcome hMSCs standardization and supply based problems, the generation of immortalized 
hMSCs was developed through the insertion of a human telomerase catalytic subunit (hTERT) (Boker, 
Yin, Drosse, Haasters, Rossmann, Wierer, Popov, Locher, Mutschler, Docheva, and Schieker, 
2008;Huang, Zheng, Sun, Guo, Yang, Chen, Xu, Wang, Shen, Pan, Jin, and Wang, 2008;Jun, Lee, 
Cho, Suh, and Jung, 2004;Piper, Wang, Yamamoto, Malek, Luu, Kuo, and Kim, 2012;Simonsen, 
Rosada, Serakinci, Justesen, Stenderup, Rattan, Jensen, and Kassem, 2002a). The generation of 
hTERT-MSCs lines allowed extended hMSCs lifespan (>300PD) and was shown to preserve some of 
the properties of primary hMSCs, such as their multilineage differentiation potential (towards 
osteogenesis, chondrogenesis and adipogenesis) (Abdallah, Haack-Sorensen, Burns, Elsnab, Jakob, 
 Hokland, and Kassem, 2005;Jun et al., 2004;Mihara, Imai, Coustan-Smith, Dome, Dominici, Vanin, 
and Campana, 2003)  and bone formation capacity (Simonsen, Rosada, Serakinci, Justesen, Stenderup, 
Rattan, Jensen, and Kassem, 2002b).  
The enthusiasm raised by the availability of an unlimited cell source with stabilized properties was 
however tempered by safety aspects. A strong telomerase expression was in fact associated with many 
cancer types (Counter, Hahn, Wei, Caddle, Beijersbergen, Lansdorp, Sedivy, and Weinberg, 
1998;Latil, Vidaud, Valeri, Fournier, Vidaud, Lidereau, Cussenot, and Biache, 2000), and neoplastic 
changes have been reported following hTERT-transformation of hMSCs (Burns, Abdallah, Guldberg, 
Rygaard, Schroder, and Kassem, 2005;Serakinci, Guldberg, Burns, Abdallah, Schrodder, Jensen, and 
Kassem, 2004) resulting in uncontrolled cell growth. Such risk may be aggravated if hMSCs are 
delivered within a 3D matrix as opposed to systemic infusion, due to the previously reported enhanced 
long-term engraftment (Daga, Muraglia, Quarto, Cancedda, and Corte, 2002). 
An elegant approach was recently proposed to enhance the safety of cellular therapies by the use of an 
inducible death-system (iDS) (Ramos, Asgari, Liu, Yvon, Heslop, Rooney, Brenner, and Dotti, 
2010;Straathof, Pule, Yotnda, Dotti, Vanin, Brenner, Heslop, Spencer, and Rooney, 2005), based on 
the expression of a modified caspase 9 (iCasp9).  
Beyond safety considerations, the introduction of an iDS may additionally offer the unprecedented 
opportunity to temporally control the survival of the transduced cells, in order to investigate their 
functional role in in vitro or in vivo models. However, while the device demonstrated a great 
efficiency in primary cells (Ramos et al., 2010;Straathof et al., 2005), no study has yet reported its 
functionality in immortalized cells. The concept may in fact be challenged by the fact that a hTERT 
over-expression has been previously associated to  cell-suicide inhibition (Deeb, Gao, Liu, Kim, 
Pindolia, Arbab, and Gautam, 2012;Indran, Hande, and Pervaiz, 2011;Liang, Ye, Dai, Shen, and Xu, 
2012),  conferring notably a resistance to caspase-mediated apoptosis (Bermudez, Erasso, Johnson, 
Alfonso, Lowell, and Kruk, 2006). 
Towards the standardized, controlled and versatile use of hMSCs, we then aimed at assessing the 
feasibility to associate immortalization and `inducible-death’ concepts to generate a hTERT-hMSCs 
line efficiently inducible to apoptosis and maintaining the typical properties of primary hMSCs. The 
 successful hTERT and iDS combination is expected to lead to the generation of an unlimited and well 
characterized hMSCs source with controlled survival, opening a variety of applications for research 
and pre-clinical purposes. 
 
Materials and Methods 
Cell culture 
Cell isolation 
Human bone marrow aspirates were obtained during routine orthopedic surgical procedures involving 
exposure of the iliac crest, after ethical approval (EKBB, Ref.78/07) and informed donor consent.  
Marrow aspirates (20 ml volumes) were harvested from a healthy donor (female, 51 year’s old) using a 
bone marrow biopsy needle inserted through the cortical bone and immediately transferred into plastic 
tubes containing 15,000 IU heparin. After diluting the marrow aspirates with phosphate buffered 
saline (PBS) at a ratio of 1:4, nucleated cells were isolated using a density gradient solution 
(Histopaque, Sigma Chemical, Buchs, CH). Complete medium consisted of either Dulbecco’s 
modified Eagle medium (DMEM) or α-minimum essential Medium (αMEM) with 10% fetal bovine 
serum, 1% HEPES (1M), 1% Sodium pyruvate (100mM) and 1% of Penicillin-Streptomycin-Glutamin 
(100X) solution (all from Gibco). Nucleated cells were plated at a density of 3.106cells/cm2 in 
complete medium supplemented with 5 ng/ml of fibroblast growth factor-2 (FGF-2, R&D Systems) 
and cultured in a humidified 37C°/5% CO2 incubator. In immortalized cell cultures, FGF-2 supply was 
interrupted after 140 PD, due to both the steady proliferation observed even in its absence and the 
possible impairment of the multi-lineage potential of hMSCs (Lai, Krishnappa, and Phinney, 2011). 
Medium was changed twice in a week. HMSCs were selected on the basis of adhesion and 
proliferation on the plastic substrate 1 week after seeding. 
 
 
 
 
 
 Cell engineering 
Immortalization 
Immortalization was performed by the use of a lentivirus Lenti-hTERT-eGFP (LG508, Biogenova). 
Infection of hMSCs was performed 1 week after isolation and plating of the nucleated cell fraction 
from bone marrow aspirate. The virus was delivered at a Multiplicity Of Infection (MOI) of 5 in 
complete medium supplemented with 8µg/mL of polybrene (Sigma Aldrich). The MOI was selected 
following preliminary experiments, in order to obtain a high transduction efficiency while preserving 
the cell functionality. The success of immortalization was assessed by flow cytometry (eGFP 
expression), telomerase activity measurement (TraP assay, Millipore, cat# S7700), a senescence assay 
(β-galactosidase assay, Sigma Aldrich, cat# CS0030) and by following the population doublings (PD) 
of the cells. The formula (PD(n/(n-1)=(log(Nn/Nn-1))/log2 was used for the calculations of the PD at 
passage n, based on the number N of counted cells. The cumulative population doubling levels (PDL) 
is the sum of population doublings (PD) across each serial passage. 
 
Retrovirus production  
The retro-vector carrying the modified caspase 9 and CD19 (iCasp9-∆CD19) was kindly provided by 
Dr. Carlos Almeida Ramos (Baylor College of Medicine, Houston, Texas, USA). The retrovirus was 
produced after transfecting the phoenix ECO cell line (American Type Culture Collection, cat# 
SD3444;) with the iCasp9-∆CD19 vector. Virus containing supernatant was collected every 12 hours, 
passed through a 0.45 µm filter and conserved at -80°C. 
The MSCV Luciferase PGK-hygro plasmid (Addgene plasmid 18782) was used for the production of 
retrovirus carrying the luciferase system (retro-Lucif). The virus production was performed using the 
same protocol as for the iCasp9-∆CD19 retrovirus. Cells were selected by hygromycin B (Sigma, cat# 
H3274) treatment for 2 weeks. 
 
Retroviral transduction 
HMSCs were plated at 6000 cells/cm2 in 60-mm dishes the day preceding the transduction. Cells were 
transduced by incubation with retroviral vector supernatants supplemented with 8 µg/ µL of polybrene 
 (SigmaAldrich) for 5 minutes at 37°C and centrifuged at 1100g for 30 min at room temperature in the 
dishes, followed by fresh medium replacement. 
 
Cell sorting 
HMSCs stably expressing hTERT-eGFP and/or iCasp9-∆CD19 were purified using a FACS-Vantage 
SE cell sorter (Becton Dickinson, Basel, Switzerland). Cells were sorted after immortalization and 
iCasp9-∆CD19 transduction at 30 PDL and 195 PDL respectively. Prior to sorting of the CD19 
positive fraction, cells were labeled using a human anti CD19-PerCP antibody (BD biosciences, cat# 
561295). 
 
Cell Characterization 
Cell phenotyping 
HMSCs phenotype was determined by cytofluometry analysis with fluorochrome-conjugated 
antibodies to human CD44 (cat# 559942), CD29 (cat# 555443), CD73 (cat# 560847), CD90 (cat# 
559869), CD34 (cat# 555822), CD45 (cat# 555483), CD146 (cat# 550315), CD19 (cat# 561295), 
Epcam (cat# 347200) all from BD Pharmingen, and E-cadherin (cat#FAB18381P) from R&D 
Systems. 
 
Adipogenic differentiation 
HMSCs were differentiated as previously described (Barbero, Ploegert, Heberer, and Martin, 
2003;Jaiswal, Haynesworth, Caplan, and Bruder, 1997;Jakob, Demarteau, Schafer, Hintermann, Dick, 
Heberer, and Martin, 2001). Briefly, cells were seeded at 3000 cells/cm2 and cultured for 1 week in 
DMEM complete medium without passage. During the following 2 weeks, cells were exposed to four 
differentiation cycles consisting in alternating `strong’ adipogenic medium (Dexamethasone 10-6 M, 
Indomethacin, Insulin, IBMX) for 3 days and `light’ adipogenic medium (Insulin) for 1 day.  
 
 
 
 Osteogenic differentiation 
HMSCs were seeded at 3000 cells/cm2 and differentiated for 3 weeks in osteogenic medium (OM). 
Osteogenic medium consists in αMEM complete medium supplemented with 10 nM Dexamethasone, 
0.1 mM L-ascorbic acid-2-phosphate and 10 mM β-glycerophosphate (Maniatopoulos, Sodek, and 
Melcher, 1988).  
 
Chondrogenic differentiation 
Culture of hMSCs was performed in 0.5 ml of DMEM containing 4.5 mg/ml D-Glucose, 0.1mM 
nonessential amino acids, 1mM sodium pyruvate, 100mM HEPES buffer, 100 U/ml penicillin, 100 
mg/ml streptomycin, and 0.29 mg/ml L-glutamine supplemented with 0.1mM ascorbic acid 2-
phosphate, 10 ng/ml TGFb1 and 10-7 M dexamethasone (Chondrogenic medium) as previously 
described (Jakob et al., 2001). Cells (350,000) were centrifuged in 1.5 ml conical polypropylene tubes 
(Sarstedt, Numbrecht, Germany) to form spherical pellets. After 2 weeks of culture, pellets were 
processed for histology and gene expression analysis.  
 
Real-time PCR 
Total RNA was extracted from cells using TRIzol (Invitrogen, Carlsbad, CA), treated with DNAse and 
retrotranscribed into cDNA, as previously described (Frank, Heim, Jakob, Barbero, Schafer, Bendik, 
Dick, Heberer, and Martin, 2002). Real-time PCR was performed with the ABIPrism 77000 Sequence 
Detection System (Perkin Elmer/Applied Biosystem, Rotkreuz, Switzerland) and expression levels of 
genes of interest were normalized to GAPDH. Primers and probe sets of chondrogenic and osteogenic 
genes were used as previously described (Frank et al., 2002). Human PPARγ (Hs00234592_m1) 
Retinoblastoma 1, p53 (Hs01034249), p21 (Hs00355782_m1) primers and probe were provided by 
Applied Biosystem. Probe and primers for c-Myc were ordered from Mycrosynth© and designed as 
follow:  
forward GCCACGTCTCCACACATCAG  
reverse TCTTGGCAGCAGGATAGTCCTT 
probe ACGCAGCGCCTCCCTCCACTC 
 Biochemical Stainings 
Alizarin red, oil red-O and Alcian blue biochemical stainings were used to respectively assess the 
osteogenic, adipogenic and chondrogenic differentiation of the cells, as previously described (Barbero 
et al., 2003;Jaiswal et al., 1997;Jakob et al., 2001). 
 
Tumorigenicity assay 
One million M-SOD cells previously transduced with the retro-Lucif virus were mixed with Matrigel 
Matrix (BD Biosciences) in a ratio 1:1 (V/V) with PBS and injected subcutaneously into the left flank 
of NOD/SCID mice (8-10 weeks old mice), initially obtained by Charles River Laboratories 
(Germany). Eventual tumor growth was monitored both weekly by palpation and by in vivo 
luminescence signal acquisition using an ISIS luminometer system. Prior to acquisition, mice received 
an intraperitoneal injection of 300µL of D-Luciferin Potassium salt (Goldbiotechnology) at 15 mg/mL. 
Cells were tracked for a period of 6 months post-injection. 
 
In vivo bone formation 
In vivo ectopic bone formation was assessed as previously described (Braccini, Wendt, Jaquiery, 
Jakob, Heberer, Kenins, Wodnar-Filipowicz, Quarto, and Martin, 2005). Briefly, cells were 
resuspended in 30µl of Fibrinogen (20 mg/ml Baxter, Austria), mixed with 30µl of Thrombin (6 
IU/ml Baxter, Austria) and immediately loaded onto 35µg of bovine bone-derived granules (Actifuse, 
Apatech, Baxter, Austria). The constructs were transferred for 15 minutes in a humidified incubator at 
37 °C with 5% CO2 to allow fibrin polymerization and implanted subcutaneously in CD-1 nu/nu nude 
mice (Charles River, Germany). After 8 weeks, the constructs were harvested, fixed overnight in 4% 
formalin, decalcified with a decalcification solution made of 7% EDTA (Sigma, cat# E5134) and  10% 
sucrose (Sigma, cat# S9378), paraffin embedded and 5µm-thick-sections were obtained from different 
levels. Sections were stained with Masson’s trichrome and observed microscopically to detect 
histological features of bone tissue. For fluorescence analysis, samples were fixed in 1.5% 
paraformaldehyde, decalcified with 7% EDTA (Sigma, cat# E5134), embedded in optimal cutting 
 temperature, and snap frozen in liquid nitrogen. Sections (5 µm thick) were incubated with DAPI to 
stain nuclei. Fluorescence images were acquired using an Olympus BX-61 confocal microscope. 
 
Immunomodulation assay (CFSE) 
The immunomodulation of hMSCs was assessed as previously described (Gattinoni, Lugli, Ji, Pos, 
Paulos, Quigley, Almeida, Gostick, Yu, Carpenito, Wang, Douek, Price, June, Marincola, Roederer, 
and Restifo, 2011). Briefly, hMSCs were seeded in 96-well plates at 20.000, 10.000, 5000 and 2000 
cells/well. CD4+ lymphocytes were extracted from whole blood PBMCs by magnetic beads labeling 
(Miltenyi Biotec) and seeded on top of hMSCs at 1*10^5 cells per well after labeling with 2 µM CFSE 
(7 min at 37 °C). The CD4+cells were left untreated or stimulated with 1 µg/mL of 
phytohemagglutinin and the proliferation index was determined after 4 days by flow cytometry and 
analyzed with FlowJo software (Treestar). 
 
Death induction 
The B/B homodimerizer (Clontech, cat# 635060) was added at 50 nM to iCasp9-∆CD19 transduced 
HMSCs in culture medium to activate the apoptosis pathway through the dimerization of the modified 
caspase 9. Percentage of induced death was assessed 12 hours later by FACS analysis, after cell 
harvest and staining with Annexin V-APC (BD Biosciences, cat#550475) and Propidium Iodide (PI, 
BD Biosciences, cat# 51-66211E) in Annexin-V binding buffer (BD Biosciences, cat# 556454). 
Control cells were cultured in the same medium without exposure to the homodimerizer. 
 
Statistical analysis 
Data are presented as means ± standard error. The significance of differences was evaluated using 
analysis of variance (ANOVA) followed by the Bonferroni test for every set of data on which multiple 
comparisons were performed. For single comparison, Mann-Whitney test was used. P < 0.05 was 
considered to indicate statistical significance. 
 
 
 Results 
Immortalization of human bone marrow derived Mesenchymal stromal cells 
Primary hMSCs were transduced with a lentivirus carrying the human telomerase gene (figure 1A). 
The rate of transduction was assessed by flow cytometry through the enhanced GFP (eGFP) reporter 
gene. After transduction, 78% of the cell population expressed the transgene. The eGFP positive 
fraction was sorted to increase the purity of the transduced population (Supp. data 1). The 
immortalized population (hTERT-hMSCs) stably displayed higher telomerase activity (4.4 ±1.5 fold) 
than their primary counterpart (primary hMSCs), even after extensive proliferation (shown up to 150 
doublings, figure 1B). Primary hMSCs did not proliferate for more than 35 PD, while the 
immortalized hMSCs underwent more than 270 PD (figure 1C). Primary cells became senescent after 
35 PD as assessed by β-galactosidase staining, while the transduced population bypassed the 
senescence associated crisis (figure 1D). The clonogenicity of the immortalized population was about 
8-fold higher than for primary hMSCs (9.3% vs 80.3%). A stable hTERT-hMSCs line with steady 
proliferation capacity was thus successfully generated. 
 
Generation of a clonal hTERT-iDS hMSCs line 
After 170 PD, the hTERT-hMSCs line was transduced with the retrovirus carrying an inducible death 
system (iDS), including CD19 as reporter gene (figure 1E). After one round of transduction, more than 
50% of the cells expressed CD19. After sorting, more than 98% of the cells expressed the reporter 
gene (figure 1F), resulting in the isolation of a stable hMSCs line uniformly carrying the death-
inducible system (hTERT-iDS). The functionality of the iDS was investigated by exposing the 
hTERT-iDS line to the Chemical Inducer of Dimerization (CID), leading to the activation of the 
suicide system. Following overnight exposure to CID (figure 1G and supplemental online video 1), 
more than 99% of the cells were pushed toward death (PI-positive or Annexin-V-positive). No toxicity 
was induced by exposing primary hMSCs or hTERT-hMSCs to CID. An immortalized and death-
inducible hMSCs line was thus successfully generated, demonstrating the possibility to combine a 
hTERT overexpression with an efficient iDS-mediated killing.  
 The immortalization process, combined with the insertion of the iDS and the extensive number of PD, 
gave rise to a likely heterogeneous cell line. In order to obtain a more uniform population, thirty single 
colonies were picked and 24 of those could be successfully expanded. We then arbitrarily decided to 
select the clone with the most prominent osteogenic differentiation capacity, as this is considered the 
common, default differentiation pathway for hMSCs (Muraglia, Cancedda, and Quarto, 2000).  
Following culture for 3 weeks in osteogenic differentiation medium, the clone displaying the strongest 
intensity of alizarin red staining was selected (Supp. Data 2). The immortalized hMSC clone carrying 
the iDS was then denominated as the Mesenchymal-Sword Of Damocles (M-SOD) cell line for further 
characterization. 
 
Phenotypic analysis of primary hMSCs and the generated cell line(s)  
The phenotype of the cell line was cytofluorimetrically assessed at different doublings and after each 
genetic modification (table 1). All transformed cells expressed typical hMSCs markers (positivity for 
CD44, CD29, CD73, and CD90) while being negative for both the hematopoietic markers CD34 and 
CD45 and the epithelial markers EpCam and E-cadherin. The immortalized population was also 
shown to increasingly express the CD146 marker following FGF-2 removal from the supplemented 
medium (at 140 PD), consistently with a previous study (Sacchetti, Funari, Michienzi, Di, Piersanti, 
Saggio, Tagliafico, Ferrari, Robey, Riminucci, and Bianco, 2007). The successive genetic 
modifications and extensive proliferation of the cell line was thus shown to not lead to an alteration of 
the mesenchymal phenotype, as assessed by conventional markers. 
 
Differentiation capacity of M-SOD line 
The multilineage differentiation capacity of the M-SOD line was tested after different numbers of 
population doublings (ranging from 250PD to over 280PD) in order to investigate the stability of M-
SOD properties. Data presented below are the average of 4 different experimental runs. 
After 3 weeks of culture in osteogenic medium (OM), M-SOD cells deposited a thick mineralized 
matrix, as demonstrated by positive alizarin red staining (figure 2A). A strong induction of key 
 osteogenic genes (figure 2B) was detected after 2 weeks of culture in osteogenic conditions (94.8-, 
8.5-, 130.9-, 16.1- and 58.7-fold for ALP, BMP-2, BSP, OC and RunX2 genes respectively, p<0.05). 
The M-SOD line was thereby shown to be capable to efficiently differentiate toward the osteogenic 
lineage. 
After 3 weeks of culture in adipogenic medium, M-SOD cells were successfully differentiated into 
adipocytes, as revealed by the positive Oil red-O staining of the lipid droplets (figure 3A). The 
upregulation of the adipogenic PPARγ gene (16.2-fold, figure 3B, p<0.05) confirmed the capacity of 
the M-SOD line to differentiate toward the adipogenic lineage. 
The chondrogenic differentiation capacity of the M-SOD line was assessed by Alcian blue staining 
after pellet culture in complete or chondrogenic medium (figure 3D). M-SOD cells did not generate a 
GAG-rich cartilaginous matrix and did not significantly upregulate Sox-9 (data not shown) or type II 
Collagen, despite a marked increase in type X Collagen gene expression level (291-fold, figure 3E, 
p<0.05). Nevertheless, the primary donor from whom the M-SOD line was derived was also not 
capable to differentiate toward the chondrogenic lineage (Supp. data 3). This suggests that M-SOD 
low chondrogenic capacity may not be due to the successive genetic modifications or the extensive 
doublings.  
 
Death induction upon osteogenic and adipogenic differentiation 
The chromatin remodeling that occurs during cell differentiation (Benayahu, Akavia, and Shur, 
2007;Siddiqi, Mills, and Matushansky, 2010) can potentially lead to the silencing of the implemented 
iDS. Consequently, the functionality of the iDS system had to be demonstrated also during cell 
differentiation. 
The death induction efficiency of the M-SOD line was tested during osteogenic or adipogenic 
differentiation, using cells expanded for different numbers of population doublings (ranging from 250 
to over 280). Data presented below are the average of 3 different experimental runs. 
During osteogenic differentiation, cells were induced with CID after 1, 2 or 3 weeks of culture in 
osteogenic medium. After an overnight exposure to CID, a very high killing efficiency was reached 
 (97.7 ±2.1%, figure 2C, p<0.0001) irrespective of the cell differentiation stage. Similar results were 
obtained by inducing M-SOD cells during adipogenic differentiation (97.1 ±2.5%, figure 3C, 
p<0.0001). The iDS implemented within the M-SOD cell line thus remained highly efficient 
independently of the differentiation status. 
 
Bone formation capacity of the M-SOD line 
The bone formation capacity was assessed by combining 1 million of M-SOD cells together with 
ceramic granules, in a fibrinogen/thrombin gel, followed by ectopic implantation in nude mice (n=3) 
for 8 weeks. Samples were retrieved, fixed and decalcified prior to sectioning and histological 
analysis.  The cells secreted a dense collagen matrix and the formation of bone nodules was observed 
within the constructs, as demonstrated by Masson’s trichrome staining (figure 4A). GFP positive cells 
were observed at the outer regions of those nodules, indicating their contribution in the deposition of 
the osteoid tissue (figure 4B).  
 
Immunomodulation capacity 
HMSCs are known to exhibit immunomodulatory properties, which include the regulation of T-cells 
proliferation. This intrinsic hMSCs capacity has been proposed to be critical towards hMSCs 
application for graft versus-host or autoimmune diseases. 
To assess whether the M-SOD line could regulate activated lymphocyte proliferation, CD4+ cells were 
labeled with CFSE and co-cultured with M-SOD cells at different ratios. The proliferation of CD4+ 
cells was measured 4 days post activation with phytohemagglutinin (PHA), by flow cytometry (figure 
4C). In the absence of PHA, CD4+ cells did not proliferate, independently of the presence or not of M-
SOD cells, implying that M-SOD cells alone did not trigger an immune reaction. In the presence of 
PHA but in absence of M-SOD, CD4+ got activated and strongly proliferated (>80%), as shown by the 
5 peaks of fluorescence observed, corresponding to 4 division cycles (figure 4D). M-SOD cells were 
able to inhibit such proliferation in a dose dependent manner (figure 4C). In particular, a 1:5 CD4+/M-
SOD ratio resulted in only one division of CD4+ cells (figure 4D). The M-SOD cell line thus 
displayed antiproliferative properties on activated CD4+ lymphocytes. In this regard, although further 
 in vivo studies would be required to fully assess the regulatory properties, to the best of our knowledge 
the M-SOD line is the first reported bone-marrow derived hMSCs line capable of immunomodulation. 
 
Oncogenes expression level and tumorigenicity assessment 
Cell immortalization, as any genetic modification, can result in a malignant transformation by 
impairing the cell cycle regulation. Key proteins, such as p53, p21, retinoblastoma-1 or c-Myc, are 
known to play an important role as cell cycle regulators, keeping cell proliferation and DNA 
replication under control (Sharpless and Depinho, 2004). The genes p53, p21, retinoblastoma-1 (Rb-1) 
and c-Myc were expressed to a similar extent in M-SOD and the primary hMSCs (figure 5A), as 
shown by the limited fold differences (2.0 ±0.4, 3.3 ±3.1, 1.3 ±0.2 and 2.5 ±0.6 fold for p53, p21, Rb-1 
and c-Myc respectively). The M-SOD cell line thus keeps expressing normal levels of cell cycle 
regulator genes. 
The tumorigenicity of the M-SOD cell line was then investigated in vivo by subcutaneous injection in 
the flank of NOD/SCID mice of one million M-SOD cells, previously transduced with a luciferase 
reporter system (retro-Lucif). Within few days, the luminescence intensity remained focalized and 
rapidly decreased, suggesting the non-proliferation or dissemination of M-SOD cells (figure 5B). After 
more than 180 days post-injection, neither luminescence nor tumor formation was detected, indicating 
the non-tumorigenicity of M-SOD cells in vivo. 
 
Discussion 
By combining two typically opposing concepts, namely immortalization and death-induction, we 
generated a hMSCs line with standardized properties and temporal control over survival. In particular, 
the M-SOD line was shown to: a) steadily proliferate, b) differentiate toward the osteogenic and 
adipogenic lineages, c) maintain the in vivo bone forming capacity, d) regulate the proliferation of 
activated lymphocytes and e) be efficiently inducible toward death using a clinically approved 
compound (Ramos et al., 2010). 
 This study demonstrates the feasibility to induce an optimal killing of hMSCs despite their previous 
immortalization. The finding is not obvious, since the hTERT expression was previously shown to 
reduce the activation of caspases 3, 8, and 9, and of pro-apoptotic mitochondrial proteins, while 
increasing the expression of the anti-apoptotic mitochondrial protein Bcl-2 (Deeb et al., 2012;Indran et 
al., 2011;Liang et al., 2012). The constitutive expression of the inducible caspase 9 combined with its 
downstream role in the apoptotic pathway, allowed to bypass the hTERT-associated resistance to 
apoptosis (Deeb et al., 2012;Indran et al., 2011;Liang et al., 2012), ensuring a control over the cell 
survival in both un-differentiated and differentiated states.  
The M-SOD properties appeared to derive from the primary cells. In fact, the strong osteogenic 
potency and limited chondrogenic potential could be related to the selection of the M-SOD clone as 
the one with the highest osteogenic differentiation capacity and to the poor chondrogenic ability of the 
primary hMSCs. Further studies are needed to confirm that the use of a primary donor or of a clone 
with a higher chondrogenic capacity would lead to the generation of a line capable to more efficiently 
undergo chondrogenesis.  
The use of immortalized hMSCs with stabilized properties offers standardization opportunity for 
research purposes. This is in contrast to primary hMSCs, which after extensive in vitro culture 
undergo senescence or possibly degenerate into malignant cells (Ben-David, Mayshar, and 
Benvenisty, 2011;Stenderup et al., 2003;Tarte, Gaillard, Lataillade, Fouillard, Becker, Mossafa, 
Tchirkov, Rouard, Henry, Splingard, Dulong, Monnier, Gourmelon, Gorin, and Sensebe, 2010). The 
disposal of an unlimited cell source also allows a clonal screening and extensive characterization, as 
well as the long-term monitoring of the population. This might be particularly of interest when 
introducing further genetic modifications, allowing a full characterization from the integration site to 
the stability and expression level of the transgene.  
Despite the random virus-derived integrations, known to potentially lead to malignant transformations 
(Du, Jenkins, and Copeland, 2005;Nienhuis, Dunbar, and Sorrentino, 2006), the M-SOD was 
demonstrated to be non-tumorigenic, both by assessment of the expression levels of cell proliferation 
and DNA replication gatekeepers, as well as by a standard in vivo test. The method can also be further 
 optimized by combining hTERT and the iDS in a same lentivector, under the control of a unique 
promoter. Eventually, placing the hTERT gene behind the iDS at the 3’ end can ensure the systematic 
hTERT silencing in case of chromatin remodelling (through either a silencing in 5’ of the promoter or 
the direct silencing of hTERT in 3’). This principle would reduce the number of transductions and 
guarantee an intrinsic control of successfully immortalized cells by the iDS. Taken together, the non-
tumorigenic engineering of M-SOD cells, combined with the control ensured by the iDS, support the 
relevance of the developed strategy as a first step in the perspective of a clinical use. In this regard, 
safety concerns would anyway require to be more comprehensively addressed by a panel of additional 
methods (e.g. karyotypic or micro-array analysis), in order to propose the iDS-hTERT strategy for 
clinical purposes.  
The diversity of hMSCs applications in regenerative medicine makes the M-SOD line an attractive 
experimental tool for a variety of contexts (figure 6). Beyond representing a standard and stable 
hMSCs source, the iDS activation could serve for the selective and temporally controlled cell 
elimination. This would be relevant in in vitro models, e.g. to study stage-specific cell-cell 
conditioning in co-culture systems, or in in vivo models, e.g. to address the question of how long the 
living hMSCs fraction is required in order to induce specific regenerative/tumor targeting effects or to 
be effective in the treatment of immune-related disorders. The M-SOD line can also be seen as a 
cellular platform that can undergo additional genetic modifications to overexpress defined factors and 
thus acting as drug carrier. This could be especially relevant to study the treatment of cancer, 
inflammatory or autoimmune diseases through the secretion of e.g. TRAIL or IFN-γ (Dai, Moniri, 
Zeng, Zhou, Rayat, and Warnock, 2011;Yang, Wu, Mao, Bao, Gao, Zhou, Xie, Zhou, and Zhu, 2009). 
In this regard, the induction of the iDS offers the possibility to switch off the expression of 
implemented transgenes and thus to temporally control the factor delivery. The efficiency of killing of 
the M-SOD in vivo could be inferred based on a previous study using the same iDS and analysis of 
residual cells by luciferase detection (). However, a stringent and quantitative assessment of the in vivo 
killing efficiency would require further transformation of the M-SOD line to express a gene allowing 
for their sensitive, non-invasive in vivo tracking (e.g., production of species-mismatched 
erythropoietin (Daga et al., 2002)), which goes beyond the scope of the present work.  
 Finally, the M-SOD line represents a unique tool to engineer devitalized cell-laid matrices with the 
capacity to induce or regulate regenerative processes, e.g. to promote bone formation (Sadr, 
Pippenger, Scherberich, Wendt, Mantero, Martin, and Papadimitropoulos, 2012). The M-SOD line 
would address standardization issues but also allow the devitalization of the engineered matrices upon 
iDS activation, prior to off-the-shelf storage. As compared to existing devitalization methods (e.g., 
Freeze & thaw cycles or the use of detergents), the iDS would better preserve the matrix integrity 
while leading to an efficient killing of the cells in a streamlined manufacturing process. 
 
Conclusions 
The present study proposes and validates the concept of the first death-inducible cell line. Although 
the findings have been generated in the specific context of hMSCs, the paradigm can be extended to 
other cell types for distinct scientific and/or therapeutic applications. The work represents the basis 
towards the general perspective of using genetic tools not only to modify or understand cellular 
function, but also to standardize and increase the safety of cell-based therapies.  
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 Figure legends 
Table 1: Cytofluorimetric analysis of the primary cells and the generated cell line at different 
development time. The generated cell lines stably expressed conventional markers for hMSCs (CD44, 
CD29, CD73, CD90) while being negative for hematopoietic (CD34, CD45) and epithelial markers 
(Epcam, E-cadherin). The eGFP and CD19 expression respectively reflect the successful 
immortalization and iDS insertion. The successive genetic transformations and extensive doublings 
did not impair the mesenchymal phenotype of the cells. 
 
Figure 1: Generation of hTERT-iDS hMSCs line 
A) Functional map of the lenti-hTERT-eGFP (Biogenova, LG508) vector use for the immortalization 
of primary hMSCs. The system consists in a human telomerase gene and a eGFP reporter gene, under 
the control of separated CMV promoters. 
B) Telomerase activity of primary hMSCs and the immortalized population (Trap assay). The 
immortalized cells (hTERT-MSCs) displayed a higher telomerase activity (> 4-fold) than their primary 
counterpart. Despite extensive doublings, the telomerase activity of the immortalized population 
remained stable (respectively assessed at 50, 100 and 150PD). 
C) Population doubling levels of primary (black stars) and immortalized hMSCs (white dots). After 35 
doublings, the primary cells stopped to proliferate while the M-SOD cells by passed the senescence-
associated crisis. After 170PD, the inducible death system (iDS) was introduced in the immortalized 
population. The M-SOD population underwent more than 270 PD after more than one year of culture. 
D) β-galactosidase assay of primary hMSCs (35PD) and hTERT-iDS (50PD) population. The primary 
hMSCs were shown to degrade β-galactosidase (blue coloration) when reaching 35PD, indicating an 
entry in a replicative senescence phase. The immortalized population bypassed the senescence-
associated crisis and continued to proliferate. 
E) Functional map of the iCasp9-∆CD19 retrovector. The device drives the expression of a modified 
caspase 9 (iCaspas9) that can be induced toward dimerization thus leading to the activation of the 
apoptotic pathway. A 2A-like sequence between the iCaspase9 and CD19 gene ensures the cleavage of 
the CD19 surface marker from the iCaspase9, after transduction of the mRNA. 
 F) CD19 expression of the hTERT-iDS cell line. A homogenous population (>98%) could be sorted 
after CD19 labeling of the successfully transduced cells, resulting in the isolation of the hTERT-iDS 
population.  
G) Functional assessment of the inducible death system implemented in the hTERT-iDS population. 
Prior to apoptosis activation, the majority (>93.6%) of the population was shown to be negative for 
Annexin-V and PI stainings (left panel). After activation of the system by an overnight exposure to the 
Chemical Inducer Dimerization (right panel), more than 99% of the cells were killed (positivity for 
Annexin-V or PI). 
 
Figure 2: Osteogenic differentiation and killing assessment of M-SOD 
A) Alizarin red staining of M-SOD cells after 3 weeks of culture in complete (CM) or osteogenic 
medium (OM). Only in presence of osteogenic medium, cells were able to deposit a mineralized 
matrix (red nodules). Size bar = 1cm 
B) Gene expression levels of key osteoblastic genes after 14 days of culture in osteogenic medium. As 
compared to cells assessed prior to culture in OM (expanded cells), a significant upregulation of 
Alkaline Phosphatase (ALP), Bone Morphogenetic Protein 2 (BMP-2), Bone Sialoprotein, Osteocalcin 
(OC) and RunX2 (Run-related transcription factor 2) was observed. *, p<0.05. 
C) Induction of death during osteogenic differentiation of the SOD cell line. Cells were induced 
toward death (+CID) after 1, 2, or 3 weeks of culture in osteogenic medium (OM). Following 
exposure to CID, more than 95% of the cells became Annexin-V or PI positive, independently of their 
differentiation state. ***, p<0.001.    
 
Figure 3: Adipogenic/chondrogenic differentiation and killing assessment of M-SOD 
A) Oil red-O staining of M-SOD after 3 weeks of culture in complete (CM) or adipogenic medium 
(AM). In presence of adipogenic medium, the M-SOD cell line was successfully differentiated into 
adipocytes as demonstrated by the positive staining of lipid droplets. Size bar = 200µm. 
 B) PPARγ gene expression level after 3 weeks of culture in complete or adipogenic medium. In 
adipogenic conditions, a significant overexpression of PPARγ mRNA level was detected (16.2 fold), 
thus confirming the capacity of M-SOD to differentiate into adipocytes. *, p<0.05 
C) Induction of death during adipogenic differentiation of the M-SOD cell line. Cells were efficiently 
induced toward death (+CID) after 1, 2 or 3 weeks of differentiation (>95%) in adipogenic medium 
(AM). A high killing efficiency (>95%) was reached despite the differentiation of the cells. ***, 
p<0.001.    
D) Alcian blue staining of M-SOD pellets after 2 weeks of culture in complete (CM) or chondrogenic 
medium (ChM). Both culture conditions did not lead to the generation of a rich cartilaginous matrix 
(blue staining). Size bar = 100µm 
E) Collagen type II (Coll II) and type X (Coll 10) gene expression levels of M-SOD cells before 
(expanded) or after 2 weeks of pellet culture in chondrogenic medium (ChM). In chondrogenic 
conditions, only a significant overexpression of Coll 10 mRNA level was observed. ns = non-
significant. *, p<0.05 
 
Figure 4: Bone formation and Immunomodulatory capacities of M-SOD  
A) In vivo bone formation of the M-SOD cell line. Cells successfully formed bone nodules (B) in 
contact with the ceramic granules (Ce), as demonstrated by Masson’s trichrome staining (up) 8 weeks 
post in vivo implantation.Size bar = 50µm and 1 mm for the lower magnification inset. 
B) Fluorescence microscopic analysis of bone formation of the M-SOD line. The eGFP signal (green) 
surrounding the bone nodules (B), demonstrates the contribution of M-SOD cells to the formed bone. 
Size bar = 50µm. The blue signal refers to cell nuclei staining (DAPI). 
C) Immunomodulation assay (CFSE) of the M-SOD line. The percentage of proliferating CD4+ after 4 
days of culture, with different ratios of M-SOD cells, +/- PHA activation. 
D) Peaks of fluorescence in the activated CD4+, alone or in co-culture (1:5) with M-SOD cells, 4 days 
post PHA activation. In the absence of M-SOD, 5 peaks of fluorescence were observed corresponding 
to 4 division cycles. 
 
 Figure 5: Oncogenes expression levels and tumorigenicity assessment of M-SOD 
A) Gene expression levels of key oncogenes in expanded primary hMSCs and M-SOD. The primary 
hMSCs and M-SOD expressed similar levels of p53, p21, Rb1 and c-Myc. *, p<0.05. f.d = fold 
difference. 
B) Tumorigenicity assay of the M-SOD cell line. One million of M-SOD cells expressing luciferase 
were injected into the right flank of NOD/SCID mice (triplicate). Two days post cell injection, the 
luciferase system allows the localization of the M-SOD cells. After 8 days, the strength of the signal 
significantly decreased and was undetectable at day 16. More than 180 days post-injection, M-SOD 
cells remained undetectable so far demonstrating their non-tumorigenicity.  
 
Figure 6: Schematic representations of the potential applications of the M-SOD line (See Text for 
more extensive description). 
 
Supplemental data 1: 
A) FACS sorting of the immortalized population using the eGFP expression of transduced cells. After 
sorting, the population homogeneously expressed the eGFP protein (>94%), indicating the successful 
isolation of the immortalized population. 
B) Phase contrast microscopy image of the immortalized population (hTERT-MSCs, PD=65) after 
eGFP-based sorting. Cells display a typical spindle-shaped morphology. Size bar = 200µm. 
C) Fluorescence microscopy image (UV light) assessing the homogenous eGFP expression in 
successfully transduced cells (hTERT-MSCs, PD=65). Size bar = 200µm. 
 
Supplemental data 2: Alizarin red staining of the 24 clones after 3 weeks of culture in osteogenic 
medium. Among all the clones, the clone 20 was shown to be the most potent in depositing a 
mineralized matrix. All pictures were taken with a similar objective and showed a representative area 
of the well. Size bar = 500µm. 
 
Supplemental Data 3: Multilineage differentiation assays of the primary hMSCs 
 A) Alizarin red staining of the primary hMSCs from whom M-SOD was derived after 3 weeks of 
culture in complete (CM) or osteogenic medium (OM). In the presence of osteogenic medium, cells 
were able to deposit a mineralized matrix (red nodules). Size bar = 1cm 
B) Oil red-O staining of primary hMSCs after 3 weeks of culture in complete (CM) or adipogenic 
medium (AM). In the presence of adipogenic medium, the primary cells were successfully 
differentiated into adipocytes as demonstrated by the positive staining of lipid droplets. Size bar = 
100µm. 
C) Alcian blue staining of the primary hMSCs from whom M-SOD was derived. HMSCs pellets were 
stained after 2 weeks of culture in complete (CM) or chondrogenic medium (ChM). The absence of 
intense blue staining demonstrates the poor chondrogenic capacity of this donor. Size bar = 100µm. 
 
Supplemental online video 1: Timelapse microscopy video (t = 5 hours) recording the apoptotic 
induction (hTERT-MSCs) by CID delivery (t = 0) to hTERT-iDS hMSCs. Within 5h, the large 
majority of the cells were successfully induced toward apoptosis. Size bar = 500 µm. 
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a b s t r a c t
Decellularized tissues, native or engineered, are receiving increasing interest in the field of regenerative
medicine as scaffolds or implants for tissue and organ repair. The approach, which offers the opportunity
to deliver off-the-shelf bioactive materials without immuno-matching requirements, is based on the
rationale that extracellular matrix (ECM)-presented cues can be potently instructive towards regenera-
tion. However, existing decellularization protocols typically result in damage to the source ECM and do
not allow the controlled preservation of its structural, biochemical and/or biomechanical features. Here
we propose the deliberate activation of programmed cell death as a method to selectively target the
cellular component of a tissue and thereby to preserve the integrity of the decellularized ECM. In the case
of engineered tissues, the approach could be complemented by the use of (i) an immortalized cell line,
engineered to undergo apoptosis upon exposure to a chemical inducer, and (ii) a perfusion bioreactor
system, supporting efficient removal of cellular material. The combination of these tools may lead to the
streamlined development of more appropriate materials, based on engineered and decellularized ECM
and including a customized set of signals specifically designed to activate endogenous regenerative
processes.
 2013 Elsevier Ltd. All rights reserved.
1. Introduction
The extracellular matrix (ECM) is a combination of structural
and functional proteins, proteoglycans, lipids and crystals that has a
unique composition and physical properties for every tissue and
organ in the body. Acting as a reservoir for morphogens while
providing mechanical support for resident cells, ECM participates
in cell communication as well as in defining the shape and stability
of tissues [5]. ECM cues have been demonstrated to specifically
promote cell recruitment, adhesion, migration, proliferation and
differentiation in a way that reflects the functional needs and bio-
logical identity of tissues [6]. Such instructive elements may retain
at least in part their functionality even in the absence of the living
cellular component.
Based on this rationale, decellularized ECM has received
increased attention in the field of regenerative medicine as an off-
the-shelf and immune-compatible alternative to living grafts for
tissue and organ repair (Fig. 1). Decellularized ECM is expected to
induce regenerative processes not only through specific “organo-
morphic” structures [8], but also by the physiological presentation
of different cocktails of regulatory molecules in a mechanically
suitable environment. The instructive scaffold materials derived
from decellularized ECM could be activated by living cells prior to
implantation, with the assumption that ECM is capable of directing
the differentiation fate of the seeded cells [9e12]. In an even more
attractive paradigm, the decellularized ECM could be directly used
to instruct resident cells towards endogenous tissue repair by
leveraging principles of morphogenesis. Starting from decellular-
ized bone as a prototype ECM graft [13], the field has received
convincing proof-of-principle evidences of the latter approach for
epithelial [14], musculoskeletal [15] and vascular [16] tissue
regeneration, as well as for the engineering of myocardial [17],
pulmonary [4], renal [18,19] and pancreatic implants [20]. More
recently, thanks to the progress in guiding cell differentiation to-
wards specific lineages, in vitro-engineered tissues are also being
considered as a substrate for decellularization. This approach opens
the perspective to the generation of large quantities of standard-
ized, customized grafts.
A variety of chemical, enzymatic and physical procedures have
been developed to eliminate the cellular component of both native
and engineered tissues while minimally disrupting the ECM
(Box 1). Protocols described in literature tend to combine several of
these principal methods in order to increase the efficiency of
decellularization and at the same time reduce damage to the ECM
by using less destructive conditions.
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All of the abovementionedmethods, which have been subject of
several review assays [6,21e23], can reach variable degrees of
decellularization efficiency, but some problems remain common to
all. First, all existing techniques rely on cell lysis. The resulting cell
debris can then freely adsorb to the remaining matrix, leading to a
paradoxical increase in immunogenicity [24]. Second, existing
techniques have been demonstrated to alter the ECM, leading to the
degradation of some of its components [6].
In principle, maintaining the integrity of the ECM following
decellularization could support amore predictable, reproducible and
effective clinical use of the resulting material. Moreover, from a sci-
entific standpoint, preservation of the ECMwould be instrumental to
possibly identify the role of specificmolecules and their organization
in eliciting tissue repair processes. However, the typical procedures
usednecessarily implyan impairmentof theECMintegrity. Aimingat
avoiding the side effects inherent to current strategies, we propose
here an alternative approach to tissue decellularization based on the
controlled activation of programmed cell death.
2. Processes of cell death
Cell death can occur by either necrosis or apoptosis. During
necrosis, the cell membrane rapidly becomes permeable, leading to
the leakage of the intra-cellular content. Necrosis is a non-
lysosomal, uncontrolled process typically caused by external
events and signals [25], associated with distinct morphological
patterns (Fig. 2). Since necrosis involves the early loss of the
membrane integrity, it induces a massive inflammation linked to
the leakage of cellular content [26].
Instead, apoptosis is a genetically determined process, conse-
quently referred to as the “programmed cell death’’, leading to the
suicide of the cells [27,28]. Apoptosis typically occurs during tissue
and organ development but may also act as a homeostatic mech-
anism or as a means to eliminate infected or tumorigenic cells [29].
Towards the induction of apoptosis for tissue decellularization,
it is necessary to distinguish two different pathways, namely the
Fig. 1. Concept of tissue decellularization. Cell-free tissue can be generated by decellularization of native or engineered tissue. The resulting ECM can be directly transplanted into a
patient (1), entirely relying on the capacity to instruct resident cells towards endogenous tissue repair (2). Alternatively, prior to implantation the ECM can be seeded with cells that
“prime” the material (e.g., to enhance its remodeling or vascularization) and/or “get primed” toward a specific function (e.g., to proliferate or differentiate) (3). The latter implants
could induce regeneration by the combined action of the seeded and recruited cells.
Box 1
Overview of existing decellularization procedures. A more
comprehensive analysis can be found in recent reviews [6,22,23].
Acids and bases [1] react with and denature proteins, sol-
ubilize cell components and alter nucleic acids, thus
bursting cells. They are not selective and hence alter also
ECM components, especially collagens, glycosaminogly-
cans (GAG) and growth factors.
Hypertonic and hypotonic solutions [2] disrupt cells
through osmotic shock and also interfere with DNA-protein
interactions. They have a relative efficiency and do not
allow for an effective removal of cellular residues.
Detergents [3] may be ionic, non-ionic or a combination of
both. They disrupt DNA-protein, lipid and lipideprotein in-
teractions and may denature proteins. Additionally to their
action on cells, they also damage the ECM ultrastructure,
leading to a loss of collagens, growth factors and GAG.
Enzymes [4] can be used to target the remnant nucleic acids
after cell rupture or the peptide bonds which anchor the
cells to the ECM. They tend to remain in significant quan-
tities in the tissue and may provoke an additional immune
response. Prolonged exposition can also result in removal
of collagens, laminin, fibronectin, elastin and GAG, as well
as destruction of the ECM ultrastructure.
Physical methods [7] are widely used for the decellulariza-
tion of tissues. The most common ones consist of repeated
freeze and thaw cycles. Cells burst due to the formation of
intra- and extra-cellular ice crystals, which lead to drastic
changes in ion concentrations and mechanical destruction
of the cell membrane. The ice crystals also damage the ul-
trastructure and proteins contained in the ECM and can
inactivate some growth factors (e.g., Vascular Endothelial
Growth Factor (VEGF)).
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intrinsic or extrinsic ones. While the two pathways differ in their
initial activation, they converge in the final cell suicide execution
(Fig. 2). The molecular mechanisms driving both apoptotic path-
ways are highly complex and not fully understood, but can be
shortly described as follows.
The intrinsic pathway, triggered upon stress stimuli (e.g. change
of environmental conditions), is initiated by the permeabilization
of the mitochondrial outer membrane, resulting in the release of
the cytochrome-c (cyt-c) into the cytosol [30]. This protein forms a
complex called apoptosome, together with the Apoptotic protease
activating factor 1 (Apaf-1) and caspase-9. The formation of this
complex turns on the initiator caspase-9, which in turn activates
the effectors caspase-3, 6, and 7 [31e33]. Due to the essential role of
the mitochondria in this process, the intrinsic pathway is also
referred to as the “mitochondrial pathway”.
The extrinsic pathway is triggered by external signals binding to
specific cell surface death receptors (DR) of the tumor necrosis
factor family (TNF, Table 1) [34,35]. Such binding results in the
formation of a death inducing signaling complex (DISC), leading to
the transduction of the signal within the cytosol [36]. Following
caspase-8 dimerization, the same effector caspases involved in the
intrinsic route are activated.
After initiation of the suicide program by either the intrinsic or
extrinsic pathway and following the activation of the effector cas-
pases, different endonucleases and proteases respectively lead to
DNA fragmentation and the degradation of cytoskeletal and nuclear
proteins [28]. As a consequence, cytomorphological changes are
Fig. 2. Processes of cell death. Cell death occurs through either necrosis or apoptosis. Necrosis implies permeabilization of the cell membrane and consequently the leakage of the
intra-cellular content, potentially inducing massive inflammation. Instead, the activation of the apoptotic program, through either the intrinsic or extrinsic pathway, involves a
cascade of molecular events that results in cellular condensation and disruption into small apoptotic bodies. During the process, the cellular content is degraded and strictly kept
within the cell membrane, avoiding an inflammatory reaction. Abbreviations: TNFR ¼ tumor necrosis factor receptor; apaf-1 ¼ apoptotic protease activating factor 1;
cyt-c ¼ cytochrome-c.
Table 1
Death receptors of the TNF superfamily and their cognate ligands. Ab-
breviations: TNFR1 ¼ tumor necrosis factor receptor 1; TNFa ¼ Tumor
necrosis factor a; Apo-3 ¼ Apoptosis antigen 3; TRAIL ¼ TNF-related
apoptosis inducible ligand; TRAILR ¼ TNF-related apoptosis inducible
ligand receptor; NGF¼ nerve growth factor; NGFR¼ nerve growth factor
receptor; EDA ¼ ectodysplasin A; EDAR ¼ ectodysplasin A receptor
[38,39,81,82] .
Receptor Cognate ligand
TNFR1 (DR-1) TNFa
Fas/CD95 (DR-2) FasL
Apo-3 (DR-3) TL1A
TRAILR (DR-4 and DR-5) TRAIL
DR-6 Unknown
NGFR NGF
EDAR EDA
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observed like the chromatin and cytosol condensation, associated
with a global cell shrinkage [28]. As a final step, cells are disrupted
into small apoptotic bodies that are then phagocytosed by immune
cells [37]. This common end stage cellular morphology of intact
apoptotic bodies is particularly interesting when considering the
decellularization of tissues and matrices, as described below.
3. Apoptosis, the holy grail for tissue decellularization?
Existing decellularization methods require a tradeoff between
efficient cellular removal and ECM preservation, as increasing the
treatment severity for a more complete decellularization fatally
results in an enhanced ECM disruption. As a result, current decel-
lularization protocols rather aim at minimizing effects on the ECM
rather than avoiding them [6]. Here we propose an alternative
approach based on the exploitation of programmed cell death. The
apoptotic pathways can be deliberately activated through a clean
and controlled process by the delivery of appropriate signals.
Importantly, this strategy of decellularization would selectively
target the cell component of a tissue, in a way which remains
decoupled from compromising the ECM integrity.
A closer analysis of the mechanism of apoptosis identifies key
features that make it attractive in view of a decellularization
procedure. During apoptosis, the cell membrane undergoes struc-
tural changes that lead to the loss of cell contact with the ECM [38].
This combined with the reduced size of apoptotic bodies (0.5e
2 mm), cell removal with virtually no structural or functional
changes to the tissue matrix may be achievable. Moreover, during
the whole apoptotic process, the cellular content is kept strictly
within the cell membrane and the apoptotic bodies [39]. The
immunogenic cellular constituents do not leak into the surround-
ing matrix [40e42], thus preventing an unnecessary inflammatory
reaction. This is in contrast to existing decellularization techniques,
inducing a necrotic cell-death, cell bursting and the release of
immunogenic cellular material within the neighboring environ-
ment [24]. Without appropriate rinses, such material may generate
a high immune-reaction following implantation and subsequently
lead to the rejection of the graft.
A possible additional advantage of ECM decellularization by
induction of apoptosis is related to the association between the
activationof effector caspases [3,6,7] and the releaseof Prostaglandin
E2 (PGE2). This process has been recently reported to be involved in
tissue regeneration by stimulating proliferation of neighboring pro-
genitor cells [43]. Thus, decellularizing a tissue through the apoptotic
pathway may contribute to prime the matrix towards regeneration
programs through the release of key paracrine signals.
Fig. 3. Tissue decellularization by apoptosis induction within 3D perfusion bioreactor. Three different approaches are proposed in order to decellularize a tissue by apoptosis-
induction; Kiss-of-death (1), Lethal Environmental Conditioning (2), Death-engineering (3). The decellularization procedure within a 3D perfusion bioreactor system increases the
convection of the apoptotic inducer, establishes controlled environmental conditions and facilitates the washout of apoptotic bodies. In particular, when considering the decel-
lularization of engineered tissues, this system could be the basis for a streamlined process to generate an ECM and subsequently induce apoptosis within a single, closed device.
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Apoptosis is also a physiological process during embryogen-
esis, normal tissue development and immunological events. In-
duction of apoptosis, as the predominant pathway to cell death,
thus has the potential to mimic natural developmental steps in
tissue formation and remodeling [44,45]. Hence, the proposed
strategy appears to be in compliance with the recently described
concept of “developmental engineering” [46], namely the reca-
pitulation of developmental processes for the engineering of
regeneration.
4. Apoptosis induction strategies
The method used to implement the apoptotic concept for ECM
decellularization will critically determine the killing efficiency and
overall success of the strategy. Here we propose different ap-
proaches, which notably differ according to the type of pathway
(i.e., intrinsic vs. extrinsic) to be activated.
4.1. Kiss-of-death
This strategy entirely relies on the extrinsic pathway activation
through the delivery of specific ligands that bind their corre-
sponding death receptors (DRs) of the TNF superfamily (Table 1). As
the DRs are ubiquitously expressed [47], the activation of the
extrinsic apoptotic pathway can be considered for the decellulari-
zation of virtually any tissue/organ. Nevertheless, the choice of the
ligand, and consequently the type of DR to target has to be carefully
considered. While some ligands are known to specifically activate
the programmed cell death, others (DR-1, DR-3, DR-6 and EDAR)
may have also anti-apoptotic effects, leading to the activation of
survival signals [35]. Furthermore, each cell type might have a
different sensitivity to each ligand, since a differential expression of
the DRs is observed from tissue to tissue. Some cells may also be
more prone than others to escape apoptosis through the survival
pathway. For instance, TRAIL was shown to induce apoptosis in
cancer cells, but not in normal cells [48,49]. Therefore, when
elaborating a decellularization strategy, the type of DR to target
should be selected according to the specific cellular system.
A certain number of pro-apoptotic ligands were already re-
ported to successfully induce apoptosis in a variety of cell types.
Human bone marrow-derived mesenchymal stromal cells (hMSC)
were shown to be sensitive to FasL, in both an undifferentiated and
differentiated status [50]. FasL was also shown to induce apoptosis
of cardiomyocytes [51] and epidermal cells [52]. Moreover, it is
abundantly expressed in a variety of organs, such as the heart,
kidney, pancreas and the liver [53]. The delivery of TNFa was
described as an efficient inducer in lung [54] and intestinal
epithelial cells [55]. This factor also promotes chondrocyte [56] and
renal endothelial cell apoptosis [57].
This non-exhaustive list of references demonstrates the di-
versity of the studies reporting the successful use of DR ligands as
apoptotic inducers. However, none of them aimed at optimizing the
observed killing, which may require screening not only for the
appropriate ligand, but also for a suitable concentration and time of
induction. One possible optimization strategy could rely on the
combination of ligands, to generate a “customized death cocktail”.
This can be used to obtain synergistic effects, as for example one
ligand would prime cells to increase their sensitivity to a second
one. It was thus shown that treating lung fibroblast and hepato-
cytes with TNFa sensitizes them to FasL induced apoptosis [58,59].
A potential limit of the Kiss-of-death strategy possibly involves
the inflammatory effect of some ligands. A certain quantity of those
factors may remain entrapped in the ECM, requiring additional
rinsing for their removal from the graft. Furthermore, depending on
the required concentrations of the selected ligands, the process
may become costly.
4.2. Lethal-environmental-conditioning
Upon environmental stress, cells can naturally undergo
apoptosis by activation of the intrinsic “mitochondrial” pathway.
An apoptotic response could thus be induced by modulating
Fig. 4. Generationof ECM-decoratedmaterials byapoptosis-driven decellularization. A hMSC cell linewas generated and transducedwith an inducible caspase 9 gene (iCaspase 9) [71].
Cells were shown to deposit amineralized ECM (Alizarin-red staining) in Petri dishes (2D)while being efficiently inducible toward apoptosis (>95% positivity for Annexin-V and/or PI).
After perfusion-mediated seeding on porous ceramic scaffolds (3D), the cell line was capable to adhere, colonize the scaffold (MTT staining) and deposit a collagen-rich ECM. The
apoptotic decellularizationperformedwithin the bioreactor system led to the generation of an ECM-decoratedmaterialwithout ameasurable reduction of the total collagen content. As
a comparison, the freeze&thaw method applied to the same constructs resulted in a collagen loss of 74% (final content: 5.61  1.06 mg/scaffold). These findings provide a proof-of-
principle for the decellularization of ECM produced by osteogenic cells following the described apoptotic Death-engineering strategy, in a perfusion bioreactor setup.
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environmental factors, including temperature, pH, as well as
CO2/O2, nitric oxide (NO), and H2O2 content. As opposed to the
physical freeze & thaw method, leading to a necrotic response, in-
duction of apoptosis by temperature changes requires low varia-
tions, in either hyperthermic [60] or hypothermic [61] ranges.
Ideally, temperature fluctuations from 10 C to 45 C are advised,
whereby the effect on the matrix will also depend on the incuba-
tion time. NO has been described as a potent inducer of mito-
chondrial apoptosis [62], especially for cardiomyocytes [63],
pancreatic cells [64] and chondrocytes [65]. The use of hypoxic
conditions was also reported to activate the apoptotic program in
pancreatic cells [66] or cardiomyocytes [67].
The advantages of the lethal-environmental-conditioning strat-
egy rely on the minimal cost and simplicity of the setup required to
modulate and control the operating conditions. However, an effi-
cient killing might only be obtained after an extensive and possibly
multi-parametric screening for optimal conditions.
4.3. Death-engineering
This strategy relies on the activation of any of the two apoptotic
pathways by the use of a genetic approach. Since it requires the
genetic engineering of cells prior to the generation of a tissue, this
strategy relatesmainly to the decellularization of engineered grafts.
Apoptosis activation could in principle be achieved by modulating
the expression level of key genes involved in the pathway. Never-
theless, since apoptosis implies phosphorylation and dimerization
of specific molecular players, it cannot be triggered by simply
overexpressing or silencing key genes of the transduction pathway.
One possibility to engineer cells to death consists in over-
expressing death-receptors at the cell surface. This was shown to
enhance cell sensitivity to the death-inducing ligand [68] and could
thus be used in conjunction with the Kiss-of-death strategy.
An alternative option relies on the implementation of a toxic
transgene (e.g. apoptin, lectin), whose expression is under strict
control. In this regard, the use of a tight and inducible expression
system is a requirement in order to activate cell-suicide post-tissue
generation and to avoid an excessive “leakiness” that may also
result in premature cell-death. The stable integration of such a
genetic construct is also critical as existing transient expression
systems were shown to persist only from days to a few weeks
within the cells [69]. Considering modified cells would be induced
towards death after the synthesis of a tissue, which implicates an
extensive culture time, transient systems may result in a poor
killing due to the non-persistence of the genetic construct.
As a suitable genetic device addressing the above mentioned
requirements, an elegant inducible system was described [70] and
shown to lead to a high killing efficiency in transduced cells. This
device is based on the constitutive expression of a modified caspase
9, whose dimerization can be activated through the delivery of a
clinically approved inducer. This genetic approach was originally
developed to improve the safety of cell-based therapy, but
could also be used to induce the decellularization of a tissue.
The efficiency of killing was already demonstrated in primary and
differentiated hMSC [71]. The advantage of this system relies in the
absence of leakiness and the downstream activation of the
apoptotic pathway, thus avoiding activation of the survival
pathway.
The three aforementioned strategies (Kiss-of-death, lethal envi-
ronmental conditioning and death-engineering) differ in protocol but
are fully compatible and their combination may in fact synergize
the final cell killing efficiency.
5. Tissue/organ decellularization within perfusion systems
Devitalization can be considered as the first step of a decellu-
larization procedure, ultimately aiming not only at killing, but also
at removing the cellular fraction. Typical methods to eliminate the
cell debris are based on extensive rinsing but risk to either lead to
mechanical disruption of the tissue or to a non-efficient removal of
the immunogenic material. Following the concepts of whole organ
perfusion elegantly developed in the recent years [5,17], here we
propose the use of perfusion bioreactor systems combined with
induction of apoptosis in order to achieve an efficient and
controlled tissue decellularization (Fig. 3).
The use of a bioreactor systemwould allow for a superior control
of the process parameters, such as temperature or gas content,
which would be directly relevant for the lethal-environmental-
conditioning strategy. Moreover, the perfusion may enhance the
killing efficiency by increasing the convection of the pro-apoptotic
factors throughout the graft, especially while considering the Kiss-
of-death orDeath engineering strategies (Fig. 3). The use of perfusion
systemswould also play a critical role in the efficient and controlled
removal of the previously killed cellular component. Controlling
the flow patterns and associated induced shear may be of interest
during the washing step in order to eliminate the apoptotic bodies
from the ECM as they form, thus allowing for a non-invasive, yet
efficient and standardized wash-out of any cellular material.
The use of perfusion-based bioreactor systems, forcing a cell
suspension or culture medium directly through the pores of a
scaffold material, was previously shown to support the engineering
of tissues with superior properties than typical static cultures [72e
74]. Thus, one could envision a streamlined manufacturing process
for off-the-shelf decellularized grafts, whereby the same perfusion
system would be used first to develop the tissue and subsequently
to decellularize the deposited ECM. Additional features and bene-
fits of such paradigm, derived from other biotechnology settings,
would include automation, standardization, control and possibly
cost-effectiveness of the process implementation.
6. Tissues engineered to death: a proof of principle
In the context of bone regeneration, one attractive strategy is to
generate decellularized grafts with osteo-inductive properties by
decoration of materials with a cell-laid ECM. In contrast to the
delivery of over-doses of single morphogens (e.g., defined bone
Fig. 5. Alternative pathways towards the design of customized, decellularized ECM (A) Cells can be engineered (1A) to secrete specific factors/morphogens. Following 3D culture,
possibly in a bioreactor system and subsequent apoptosis-driven decellularization, the produced tissues are enriched in specific morphogens (2A). The differences in composition
are expected to trigger specific regenerative effects in vivo (3A) that could result in their direct pre-clinical/clinical translation [4]. The matching between the elicited in vivo
response (e.g. angiogenic, osteo-inductive or proliferative effect) and the ECM composition could lead to the selection of a set of factors (5A) capable to induce a desired regenerative
process. Ultimately, the design of the resulting customized ECM would represent a new generation of instructive materials with enhanced performance for a predictable regen-
eration (6). (B) The decellularization by apoptosis also offers the exciting but challenging possibility to investigate the properties of ECM from engineered/native tissues (1b),
through the removal of the cellular fraction without compromising the integrity of the ECM (2b). This may allow to better understand the role and function of the different ECMs in
the absence of the cellular component. The instructive capacity of such acellular constructs can be evaluated upon in vivo implantation in suitable models (3b) and the observed
regenerative effect can either lead to a direct pre-clinical/clinical translation of the generated ECM (4), or can be matched with the respective ECM composition (5b). A combinatorial
analysis of this matching may allow the identification of new signals (5b) that critically drove the regenerative process. Ultimately, these factors could be implemented within the
design of customized ECM (6), converging with the approach described above (Fig. 5A) towards the generation of instructive materials that contain the necessary set of signals
required for the repair of specific tissues/organs.
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morphogenetic proteins), associated with cost and safety concerns
[75,76], this approach relies on the embedding and presentation by
the ECM of a cocktail of different factors in more physiological
concentrations to activate a regenerative process (e.g., by acting on
resident osteoblastic and endothelial lineage cells). In this context,
human bone marrow-derived Mesenchymal Stromal Cells (hMSC)
have already been used in the attempt to generate ECMwith osteo-
inductive properties [77,78], as a niche for reseeded MSC or for
priming of endogenous progenitor cells. So far, however, the ECM
deposited during in vitro culture could not be shown to be capable
of inducing ectopic in vivo bone formation if deprived of the living
cellular component [9]. Combining the approaches of decellulari-
zation by apoptosis with a 3D perfusion culture system [79],
together with the utilization of a suitable cell source, could offer the
opportunity to enhance the osteo-inductive properties of decellu-
larized ECM. We recently reported the successful generation of an
immortalized hMSC line with properties similar to the original
primary cells and controlled survival. The cell line maintains the
capacity to differentiate towards the osteogenic lineage, is not
tumorigenic and e thanks to the implementation of a genetic de-
vice e can be pushed to programmed cell death by the delivery of a
clinically approved chemical inducer [80].
Here we report that the cell line could deposit a mineralized
ECM in 2D culture and still be efficiently induced towards apoptosis
(>95%, Fig. 4). Moreover, when seeded on a porous ceramic scaffold
within a 3D perfusion-based bioreactor system, the engineered cell
line was capable to adhere, proliferate and deposit an ECM. The
generated constructs could be directly and efficiently decellularized
by the direct perfusion of the apoptotic-inducer through the ECM,
leading to the successful generation of ECM-decorated, cell-free
materials. As compared to the living counterparts, the “apoptized”
tissues maintained the amount of total collagen, as representative
ECM protein, in contrast to those decellularized by a conventional
freeze/thaw protocol, where a marked loss of total collagen content
(74%) was measured (Fig. 4). This setting thus provides a proof-of-
principle for the decellularization of ECM produced by osteogenic
cells following the described apoptotic Death-engineering strategy,
in a perfusion bioreactor setup.
Further studies are required to assess (i) to which extent the
apoptotic treatment may better preserve the deposited ECM,
beyond total collagen, as compared to traditional protocols of
decellularization and (ii) whether the resulting “apoptized” grafts
have osteo-inductive properties. The paradigm could obviously be
extended to other cell lines, for the deposition of a customized ECM
specifically competent to induce regeneration of different tissues.
7. Conclusion & perspective
The deliberate activation of programmed cell death is here
proposed as an elegant alternative to conventional approaches for
decellularization of native or engineered ECM. Thanks to the pos-
sibility to specifically target the cellular component, decellulariza-
tion by apoptosis-induction is expected to better preserve the
integrity of the structural and instructive components of an ECM
and ultimately to lead to the generation of off-the-shelf grafts with
enhanced regenerative properties. The different apoptosis induc-
tion strategies described above offer a wide range of possibilities
which could also be combined with a 3D perfusion culture system
for a streamlined process implementation and/or with the use of
immortalized cell lines, genetically implemented with an inducible
death device.
The use of a cell line for the engineering of ECM to be decellu-
larized would support not only repeatable production of batches
with standardized properties, but also optimization and custom-
ization of the ECM regenerative potency. In fact, a cell line could be
further engineered to overexpress defined factors, for example
specific BMPs for enhanced osteoinduction or VEGF for more effi-
cient vascularization. The design of customized ECM (Fig. 5A) to
elicit specific repair would allow establishing a new generation of
instructive materials matching the structural and molecular cues
required for a predictable regeneration.
The use of apoptosis as decellularization technique goes beyond
the generation of grafts with enhanced performance. The concept
would also offer the unprecedented possibility to investigate the
properties of decellularized but theoretically intact ECM and e by
correlating an observed regenerative capacity with a specific
composition e to identify a set of cues critical to elicit certain
functions (Fig. 5B). The investigation and validation of the relevance
of such features could then ultimately support a transition from the
paradigm of decellularization of engineered biological ECM to the
vision of entirely synthetic matrices, designed to contain the
necessary and sufficient set of signals required for the repair of
specific tissues/organs.
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ABSTRACT 
The generation of tissue-engineered, decellularized bone substitutes appears as a promising 
alternative to existing bone repair strategies. In particular, materials combined with a cell-laid ECM 
have been proposed as instructive templates to guide residing cells toward bone formation. 
However, the instructive properties of such ECM-coated materials may highly depend on the 
decellularization procedure that can affect the structure and/or composition of the generated graft. 
The activation of programmed cell death was proposed as novel decellularization approach, in order 
to better preserve the ECM properties. Here, using a human death-inducible bone marrow-derived 
mesenchymal stromal cell (BMSC) line, we explore the possibility to generate ECM-coated constructs 
for bone regeneration purposes and to decellularize them by apoptosis induction. ECM-coated 
materials were successfully generated using a ceramic-based scaffold, by culture for 4 weeks in a 3D 
perfusion bioreactor. The resulting grafts were decellularized using either induction of apoptosis, or a 
conventional Freeze & Thaw (F&T) protocol as comparative method. While both procedures were 
shown to efficiently decellularize the constructs (>90% of cell death), the apoptotic method led to a 
better conservation of the critical ECM components (e.g. Collagens, VEGFα, IL-8, MCP-1, SDF-1 and 
M-CSF). The validation of this approach is expected to lead to a standardized procedure for the 
engineering of bone graft substitutes, which includes the combination of a standard cell source, a 
novel decellularization technique, a controlled 3D culture system and a clinically suitable ceramic 
material.  
 
 INTRODUCTION 
The healing of bone remains a major clinical issue that requires the development of alternative 
strategies capable to promote a fast, stable and efficient repair (1). Tissue engineering approaches 
proposed the in vitro generation of bone grafts, through the seeding of osteoprogenitors -such as 
BMSC-, on three-dimensional (3D) scaffolds that support cell growth, differentiation and extracellular 
matrix (ECM) deposition (2-4). The resulting engineered grafts, containing living cells, are expected to 
induce tissue regeneration upon implantation into a defect site. Nevertheless, limits aroused from 
the lack of standardization -mainly cell source dependent (5)-, and the method only leads to an 
autologous exploitation of the generated bone substitute. 
For these reasons, the development of decellularized grafts has received increased interests, as 
immune-compatible and off-the-shelf alternative to living grafts. The concept relies on the possibly 
retained osteoinductive properties of the ECM-coated scaffolding material despite the cellular 
depletion. The ECM is then perceived as a morphogen reservoir capable to instruct resident cells 
toward bone regeneration. 
The success of this strategy may depend on the use of a suitable decellularization protocol, allowing 
the efficient removal of the immunogenic cellular materials while preserving the integrity of the 
deposited ECM (6), meant to drive the in vivo bone repair. As existing strategies were shown to vary 
in their efficiency and to affect the ECM structure/composition, a paradigm shift has been recently 
proposed by the activation of the programmed cell death as decellularization technique (7). The 
induction of apoptosis is expected to lead to tissue decellularization while better preserving the ECM 
integrity. 
In this study, we aim at generating ECM-coated materials using a death-inducible BMSC line seeded 
and cultured on ceramic scaffolds in a 3D perfusion bioreactor. In particular, the activation of the 
inducible death-device was designed to serve as decellularization method. The resulting acellular 
grafts were compared to those obtained by F&T decellularization, in terms of cell removal efficiency 
and matrix preservation. We hypothesize that the apoptotic approach may better preserve the graft 
 integrity thus allowing for the generation of bone substitutes with an intrinsic increased regenerative 
potential.  
 
MATERIALS & METHODS 
Cell culture 
Cell expansion 
The previously generated M-SOD line (7) was cultured in complete medium consisting of α-minimum 
essential Medium (αMEM) with 10% fetal bovine serum, 1% HEPES (1M), 1% Sodium pyruvate 
(100mM) and 1% of Penicillin-Streptomycin-Glutamin (100X) solution (all from Gibco). Cells were 
cultured in a humidified 37C°/5% CO2 incubator and medium was changed twice in a week.  
 
Osteogenic differentiation in 2D 
M-SOD cells were seeded at 3000 cells/cm2 and differentiated for 3 weeks in osteogenic medium 
(OM). Osteogenic medium consisted of αMEM complete medium supplemented with 10 nM 
Dexamethasone, 0.1 mM L-ascorbic acid-2-phosphate and 10 mM β-glycerophosphate (8). 
 
Death-induction 
The B/B homodimerizer (Clontech, cat# 635060) was added at 50 nM in culture medium to activate 
the apoptosis pathway through the dimerization of the modified caspase 9.The percentage of 
induced death was assessed 12 hours later by FACS analysis, after cell harvest and staining with 
Annexin V-APC (BD Biosciences, cat#550475) and Propidium Iodide (PI, BD Biosciences, cat# 51-
66211E) in Annexin-V binding buffer (BD Biosciences, cat# 556454). Control cells were cultured in the 
same medium without exposure to the homodimerizer. 
 
 
 Generation of ECM-coated construct 
Cell seeding 
The 3D culture was performed using a previously developed perfusion bioreactor system (U-cup, 
Cellec Biotek AG), allowing controlled flow of a cell suspension or culture medium directly through 
the scaffold pores (9). M-SOD cells were seeded on hydroxyapatite scaffolds (Engipore®, Finceramica-
Faenza, Faenza, Italy) in the form of porous cylinders of 4 mm height and 8 mm diameter. Scaffolds 
were seeded with 0.75*10
6 of 
M-SOD cells by overnight perfusion at a superficial velocity of 1000 
μm/s in proliferation medium (PR), consisting of CM supplemented with 100 nm dexamethasone, 0.1 
mm ascorbic acid-2-phosphate and 5 ng/ml FGF-2. After 24 h (cell seeding phase), the superficial 
velocity was reduced to 100 μm/s for perfusion culture of M-SOD cells. The cell homogeneity and 
viability within constructs was assessed by methyl-tetrazolium staining (MTT, Sigma). 
Graft generation 
The protocol for the generation the of ECM-coated constructs was adapted from (10). Finally, grafts 
were generated by culturing M-SOD cells for 1 week in PR and 3 weeks in OM, within the 3D 
perfusion bioreactor system. Culture medium was changed twice a week. Samples were sacrificed at 
day 1, day 7 and day 28 to evaluate the cell seeding efficiency and cell proliferation. 
 
Graft decellularization 
The constructs were decellularized using the previously described apoptotic approach or a 
conventional F&T method. Apoptosis was induced as described above, and cell debris was removed 
by washing the constructs in sterile PBS in the perfusion bioreactor at 100 μm/s for 30 min at 37°C 
(adapted from (10)). The F&T consisted of three cycles of dry freezing in liquid nitrogen and thawing 
in a 37 °C water bath for 10 minutes each respectively. Samples were rinsed in double distilled water 
after the 1
st
 thaw in order to hypotonically lyse the cells. Subsequent to the F&T divitalization, the 
elimination of cellular debris was performed by a perfusion-based washing step: the constructs were 
placed back into the bioreactor system and perfused at 100 μm/s in PBS for 30 min at 37°C.  
  
Ostegenic differentiation assessment 
Real-time RT-PCR 
Total RNA was extracted from cells using TRIzol (Invitrogen, Carlsbad, CA), treated with DNAse and 
retrotranscribed into cDNA, as previously described (11). Real-time RT-PCR was performed with the 
ABIPrism 77000 Sequence Detection System (Perkin Elmer/Applied Biosystem, Rotkreuz, Switzerland) 
and expression levels of genes of interest were normalized to GAPDH. Primers and probe sets of 
osteogenic genes were used as previously described (11). 
 
Biochemical staining 
Alizarin red biochemical staining was used to assess the osteogenic differentiation of the cells, as 
previously described (12).  
 
Cell extraction from the 3D scaffold 
Following 3D cultures, cells were extracted from the scaffold pores by sequentially perfusing a 
solution of 0.3% collagenase (Worthington, USA) for 40 min and 0.05% trypsin/0.53 mm EDTA 
(GIBCO, Switzerland) for 10 min, both at a superficial velocity of 400 μm/s. Previous studies using a 
similar setup indicated that the protocol allows detaching of more than 85% of the total cells in the 
system (13).  
 
Osteogenic marker analysis 
M-SOD cells from the 2D or 3D generated ECM were retrieved, permeabilized for 15 min in 
permeabilization buffer (R&D systems cat# F005) and stained at 4 °C for 30 min with an antibody 
against STRO-1 (R&D systems cat# MAB1038), osteocalcin (OC, R&D systems cat# IC1419P) or 
alkalyne-phosphatase (ALP, R&D systems cat# FAB1448A).  Cells were washed and stained with an 
APC conjugated secondary antibody (R&D systems cat# IC002A) for 30 min and analyzed using a 
 FACSCalibur flow cytometer (BD Biosciences, Germany). Positive expression was defined as the level 
of fluorescence greater than 95% of the corresponding isotype control. 
 
ECM characterization 
DNA quantification 
Constructs retrieved from the bioreactor chamber were digested with proteinase K solution (1 mg/ml 
proteinase K, 50 mm TRIS, 1 mm EDTA, 1 mm iodoacetamide, and 10 μg/ml pepstatin-A; Sigma–
Aldrich, USA) in double distilled water or potassium phosphate buffer for 16 h at 56 °C as previously 
described (14). DNA quantification was performed by means of a commercially available fluorescence 
based kit, namely CyQUANT® Cell Proliferation Assay (Invitrogen, USA). Working solutions were 
prepared according to the manufacturer's protocols. The analyses were carried out measuring 
fluorescence with a Spectra Max Gemini XS Microplate Spectrofluorometer (Molecular Devices, USA). 
Excitation and emission wavelengths were respectively 485 nm and 538 nm. Samples in each plate 
included a calibration curve.  
 
Collagen and calcium quantification 
Total calcium was measured using a colorimetric-based assay. Briefly, calcium present in the 
mineralized extracellular matrix was solubilized in 0.5 N hydrochloric acid for 4h at 4°C before 
quantification (Total Calcium Assay, Randox, UK). Total collagen content was determined using the 
Sircol assay (Biocolor, UK) after samples solubilization in 3% v/v acetic acid (Fluka, Switzerland) and 
0.01% w/v pepsin (Sigma–Aldrich, USA) overnight at 4 °C. The calcium/collagen concentration was 
assessed using a Spectra Max 190 microplate colorimeter (Molecular Devices, USA) following the 
parameters provided in the respective assay kits. 
 
 
 
 Scanning electron microscopy (SEM) 
For SEM, cell-seeded constructs were fixed overnight at 4 °C with 4% formaldehyde and washed with 
PBS. Samples were gradually dehydrated with 30-50-70-90-100% ethanol, coated with gold and 
imaged with a Philips XL 30 ESEM microscope. 
 
Affymetrix-protein quantification 
Prior to and after decellularization procedures, the generated ECM coated grafts were analyzed for 
their content of a panel of growth factors, chemokines, and metalloproteinases, according to the 
manufacturer’s instructions (Procarta Immunoassay Kit; Panomics). 
 
Statistical analysis 
Data are presented as means ± standard deviation. The significance of differences was evaluated 
using Mann Whitney tests, with p< 0.05 considered to indicate statistical significance (GraphPad 
Prism 5). 
 
RESULTS 
Osteogenic differentiation of M-SOD cells and generation of 2D decellularizable ECM 
M-SOD cells were cultured for 3 weeks in osteogenic medium to assess their differentiation capacity. 
Upon 2D culture, cells displayed a typical kinetic of osteogenic differentiation (figure 1A) marked by a 
decrease in the percentage of cells expressing the stro-1 progenitor marker (9.6-fold) and ALP 
protein (5.3-fold) and increase of the later marker OC (9.9-fold) from 2 to 3 weeks of culture. The 
differentiation was confirmed by the upregulation of key osteogenic genes (figure 1B) assessed after 
3 weeks of osteogenic differentiation (6.1, 10.9 and 8.1 fold higher levels than prior to induction for 
ALP, OC and BMP-2 respectively).  
During 2D culture, M-SOD cells were shown to deposit a collagen-rich ECM (figure 2B), that 
mineralized in the presence of osteogenic medium (figure 1A) as confirmed by the high calcium 
 content (52.6 μg/mL of culture, figure 2C). Importantly, the ECM secreted by the engineered M-SOD 
cells could be decellularized by activation of the inducible-death system integrated within those cells. 
The apoptosis induction was shown to result in an efficient cell-killing (94.9%, figure 2D), thus 
demonstrating the possibility to generate decellularizable ECM in 2D. 
 
Engineering of ECM-coated constructs 
Cells were seeded on ceramic scaffolds and cultured for 4 weeks in 3D perfusion-based bioreactors in 
order to generate grafts decorated with a mineralized ECM (figure 3A). A proliferative medium (PR) 
was initially supplemented for 1 week to support cell growth and scaffold colonization. The medium 
was then switched to an osteogenic medium (OM) for 3 weeks to induce cell differentiation and 
matrix deposition.  
Following dynamic seeding on ceramic scaffold, cells continuously proliferated with the largest 
increase in cell number observed during the 1 week of culture when supplemented with proliferative 
medium (0.48 PD/day, figure 3C). During the 3 weeks of osteogenic differentiation, cells continued to 
proliferate though they displayed a reduced growth rate (0.19 PD/day, figure 3C).  
After 4 weeks of 3D culture, the constructs contained more than 6 million cells (figure 3C) rather 
homogeneously distributed within the scaffold pores (figure 4A). M-SOD cells were efficiently 
differentiated as assessed by the pattern of expression of ALP, stro-1 and OC protein (figure 4B). The 
gene expression analysis confirmed the successful differentiation of M-SOD in the 3D scaffolds as a 
strong upregulation of key genes involved in the osteoblastic differentiation was observed. As 
compared to expanded M-SOD, cells retrieved from the generated constructs upregulated ALP, OC, 
BSP, Cbfa-1, and OSX by a 12.1-, 3.2-, 6.1-, 2.1-, and 17- fold respectively (figure 4C). Interestingly, a 
strong MMP-13 over-expression was also observed (17.1- fold, figure 4C), which is required for 
collagen matrix remodeling toward bone mineralization (15).   
Taken together, these data demonstrate the successful differentiation of M-SOD during the 3D 
perfusion culture on ceramic scaffolds. 
 
 Decellularization of the generated grafts 
After 4 weeks of 3D perfusion culture, the grafts consisted in a thick ECM coating the scaffolding 
material (supp. data 1) but still containing the living cellular fraction. In order to remove the cell 
compartment, constructs were decellularized either by repeated freeze and thaw (F&T) cycles or by 
apoptotic induction through the supplementation of the chemical inducer of dimerization (CID) 
activating the M-SOD suicide device. 
Both decellularization processes led to an efficient cell death as qualitatively assessed by MTT 
staining of the construct (figure 5A). Importantly, treatments led to a similar cell killing efficiency 
(92.3% and 98.4% for F&T and CID respectively, figure 5B) while only 14% of apoptotic cells were 
measured in non-decellularized constructs. In particular, the perfusion system allowed for an 
efficient removal of the cellular fraction following F&T or CID treatment with respectively 81.4% and 
72.5% of DNA removal (figure 5C). Thus, both the apoptotic induction and F&T method allowed for a 
comparable and efficient decellularization of the generated grafts. 
 
Impact of the decellularization treatments on the produced ECM 
Although both decellularization methods led to a successful cell removal, the success of a 
decellularization strategy also relies on its ability to preserve the ECM structure and composition. 
After 4 weeks of culture, cells deposited a collagen-rich ECM (21.7μg/construct, figure 6A) coating 
the ceramic material (supp. data 1). However, the F&T decellularization resulted in an important loss 
of collagen content (74% of the pre-decellularization content) with only 5.6μg/construct remaining 
after treatment. Instead, the apoptotic induction process seemed not to affect the structural 
composition of the ECM, as no loss of collagen was observed (21.6μg/construct, figure 6A). 
The F&T treatment also led to an important loss of key ECM proteins (figure 6B). A strong reduction 
of interleukin 8 (IL-8, 17.4% of the pre-decellularization content), monocyte chemotactic protein-1 
(MCP-1, 14.2%), osteoprotegerin (OPG, 13.1%), vascular endothelial growth factor α (VEGFα, 34%), 
stromal cell-derived factor 1 (SDF-1, 13.8%), and macrophage colony-stimulating factor (M-CSF, 
79.4%) content was observed. The apoptotic method was shown to better maintain the ECM 
 proteins as no reduction of the IL-8, M-CSF and VEGFα content could be observed. A marked 
decrease of MCP-1 (66.3%), OPG (25.9%) and SDF-1 (48%) was observed, but to a lower extent as 
compared to the F&T treatment. In particular, the decrease of OPG, inhibitor of osteoclastogenesis 
(31), could be in part explained by the possible ligation of this soluble receptor to its cell-bound 
receptor (32). Thus the removal of the cellular fraction from the graft may also remove the bound 
OPG.  
 
DISCUSSION 
Using a previously described death-inducible BMSC line (7), we investigated the possibility to 
generate ECM-coated material and subsequently decellularize them by apoptosis induction.  
In this experimental setup, the M-SOD line was successfully differentiated toward the osteoblastic 
lineage and was shown to be able to deposit a collagen-rich, mineralized matrix. Importantly, the 
cells could be efficiently induced toward death after ECM deposition, thus validating for the first time 
the deliberate apoptosis activation to decellularize a pre-engineered tissue. Importantly, the 
proposed approach was shown to induce a high cell killing efficiency and allowed for an efficient 
removal of the cellular fraction. In fact, the decellularization efficiency was comparable to the well-
established F&T technique (10). However, the decellularization by apoptosis was shown to better 
preserve the deposited ECM. In particular, collagens –the most important ECM structural proteins 
(20), were shown to be conserved upon decellularization treatment, thus supporting a structural 
preservation of the graft.  
The apoptotic method also led to the better conservation of key ECM-embedded cytokines and 
morphogens, toward the use of the graft as instructive template. Indeed, crucial steps to drive a 
bone healing process include an inflammation phase and the vasculature recruitment (21-23). The 
apoptotic method led to the better preservation of IL-8 and MCP-1, both mediators of immune 
reaction (24, 25), as well as involved in the recruitment of host cells (26). Moreover, apoptosis 
preserved the VEGFα and SDF-1 contents which may be crucial for the successful engraftment of the 
constructs, as strong inducers of angiogenesis (27, 28). SDF-1 was also shown to drive the migration 
 of hematopoietic cells (29) which can be of importance toward the reconstitution of the bone 
marrow niche. In addition, M-CSF is involved in HSC differentiation (30). Overall, the superiority of 
the apoptotic method supports its use for the generation of osteo-inductive grafts. 
Using a perfusion bioreactor system, M-SOD cells were shown to actively proliferate in 3D culture 
after seeding on a ceramic scaffold, leading to the generation of homogenously ECM-coated 
constructs. If a direct comparison of 2D and 3D culture conditions might not be relevant, a superior 
differentiation of M-SOD cells was clearly observed in the 3D setup (29.9% of OC expression in 2D 
versus 82.3% in 3D). This could be partially explained by the flow-induced mechanic stimulation 
offered by the perfusion device (16) together with the enhancement of mass transport.  
The ceramic scaffold was selected for this study with the rational to provide the essential calcium-
phosphate substrates required for new bone formation (18, 19). Moreover, ceramic scaffolds are 
generally highly biocompatible and therefore promising toward the direct clinical translation of the 
approach (18). Obviously, the validation of the M-SOD cells in combination with other scaffolding 
material may be of high interest to possibly extend the range of applications. 
The instructive potential of the here engineered constructs still needs to be determined by assessing 
a possibly faster and/or increased bone regeneration than non-ECM coated or F&T treated 
constructs. Nevertheless, this approach displays key advantages over pre-existing bone repair 
strategies. Mainly, fully engineered delivery systems only allow for the release of a single or limited 
combination of growth factors, and the associated concentration and kinetic of delivery is subject to 
tuning difficulties. Instead, a natural ECM can be perceived as a growth factor reservoir that contains 
a complete set of morphogens/cytokines that can be delivered and presented at physiological –thus 
safe– dose. On the other hand, fully natural ECMs derived from decellularized native tissues (e.g. 
bone) are of limited availability and have lost in part their regenerative potential during the 
decellularization process. Thus, the proposed approach consisting in the use of cell line to decorate a 
synthetic scaffold with a natural ECM may solve availability, safety and quality issues for the effective 
clinical use of the resulting material. 
 
 CONCLUSION 
The use of the M-SOD line offers both an unlimited and standard cell-source while intrinsically 
representing an innovative decellularization tool. Together with a 3D-perfusion system that allowed 
enhancement of performance while increasing the convection of the apoptotic inducer and removal 
of cell debris, the strategy represents a significant advance for the development of an automated 
streamlined procedure for the standard generation of bone-graft substitute. Ultimately, the concept 
could be applied for the generation and subsequent decellularization of other types of tissues. 
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 FIGURES LEGENDS 
Figure 1: Osteogenic differentiation of M-SOD in 2D culture. M-SOD cells were successfully 
differentiated as demonstrated by the strong expression of the early ALP protein at 2 weeks (46.6%, 
A) and strong of the later OC marker (29.9%, A). The progenitor marker stro-1 decreases upon 
differentiation. The over-expression of key osteogenic genes measured after 3 weeks (B) confirmed 
the osteogenic differentiation of M-SOD cells (6.1, 10.9 and 8.1 fold difference for ALP, OC and BMP-
2 respectively). *, p<0.05. 
 
Figure 2: Generation of decellularizable osteogenic matrix in 2D. Upon 3 weeks of osteogenic 
differentiation, M-SOD cells were shown to be capable to deposit a mineralized, collagen-rich matrix 
as assessed by total collagen (A), alizarin-red staining (B), and calcium deposition (C). The secreted 
ECM could also be efficiently decellularized by apoptosis induction (94.9%, C). Size bar = 1cm  
 
Figure 3. 3D culture of M-SOD in perfusion bioreactor. Experimental set up leading to the generation 
of ECM-coated scaffold followed by their subsequent decellularization using a Freeze& Thaw (F&T) or 
apoptotic approach (A). The cell line demonstrated a continuous proliferation, reaching more than 6 
million cells after the 4 weeks of culture (B). 
 
Figure 4: Differentiation of M-SOD in 3D perfusion bioreactor. After 4 weeks of culture, scaffolds 
were homogenously populated with living cells (MTT staining, A). The strong OC (82.3%) and ALP 
(26.6%) expression and assessed of the successful cell differentiation, with resident progenitor cells 
revealed by low Stro-1 expression (3.7%, B). The gene expression levels of key osteogenic genes (C) 
confirmed the osteogenic differentiation of M-SOD cells in bioreactors (12.1-, 3.2-, 6.1-, 2.1-, 17-, 
17.1- fold difference for ALP, OC, BSP, Cbfa-1, OSX and MMP-13 respectively). Size bar = 0.2cm. *, 
p<0.05.  
 
 Figure 5: Decellularization of ECM-coated scaffolds. Both decellularization protocols led to an 
efficient cell killing, as assessed by MTT staining (A). Quantification by flow cytometry (B) revealed a 
similar percentage of death-induction in Freeze & Thaw (F&T, 92.3%) and apoptosis-induced samples 
(+CID, 98.4%). The decellularization processes also led to an efficient removal of the DNA material (C, 
81.4% and 72.5% respectively) with only 3309.5 ng and 4883.8 ng after F&T and apoptotic treatment 
respectively. Size bar = 0.2cm  
 
Figure 6: Effect of decellularization treatments on the ECM. The decellularization by F&T led 
to a severe loss of collagen (74%, A) while the apoptotic treatment did not impair the 
content (A). The quantification by Luminex analysis confirmed the better preservation of 
ECM proteins using the apoptosis treatment. *, p<0.05. n≥4. 
 
Supplementary data 1: Scanning electron microscopy of empty (A) and 3D engineered 
construct (B). Engineered constructs were seeded with M-SOD cells and cultured for 4 weeks 
in perfusion bioreactor, leading to the coating of the material with ECM. 
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Chapter 5  
 
Conclusion & Perspectives 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Impact on bone tissue engineering…  
The need for bone graft substitutes is in constant increase, driven by the gain in life expectancy that 
results in the aging of the population. As existing repair strategies were shown to be associated with 
subsequent drawbacks, the healing of bone remains a major and challenging health problem that 
requires the development of more effective regeneration therapies.  
Progress in stem cell biology and material science led to the emergence of different tissue 
engineered-based approaches, holding great promise. However, only few of them led to clinical 
translation as clear limitations still need to be overcome, including the demonstration of a higher 
regenerative potential over conventional treatment, the cost-effectiveness, the standardization and 
the possible immunogenicity in a non-autologous setting.  
This thesis aimed at incorporating these pre-identified requirements within the elaboration process 
of an ECM-coated ceramic material, to be used as bone graft substitute. In fact, this strategy presents 
the advantage to directly address immunogenicity issues as avoiding the previously necessary 
patient-graft matching, toward the production of a universal graft.  
In particular, chapter 1 addresses standardization issue arising from the use of conventional cell 
sources, through the generation of a well-characterized BMSC cell line. The contribution to the state-
of-the-art also includes the possible control of the cell survival through the inducible death-device 
implementation, thus overcoming typical concerns associated with the use of immortalized cells.  
As the performance of a graft is directly linked to its composition, we aimed at improving the 
decellularization treatment that undoubtedly affects the integrity of a graft, thus addressing quality 
requirements. Chapter 2 describes an innovative concept consisting in the activation of the natural 
programed cell death pathway to decellularize an engineered tissue. This original approach was 
proposed in association with a perfusion bioreactor system in order to efficiently remove the cellular 
fraction while better preserving the composition and possibly associated regenerative potential of 
the implant.  
Finally, chapter 3 demonstrated the successful combination of the developed cell line and apoptotic 
approach for the generation and subsequent apoptosis-driven decellularization of engineered 
construct, within a 3D perfusion bioreactor. This study validates the superiority of the apoptotic 
approach over existing protocols in terms of ECM preservation. In particular, the developed approach 
presents key advantages as the acellular graft is generated and subsequently decellularized within a 
single, closed culture system. As a consequence, manipulation steps are limited, which is of high 
interest toward the development of an automated, streamlined process for bone grafts production. 
Hence, this development process combined with the use of a cell line represents an important step 
toward a cost-effective graft production.  
Overall, the developed strategy allowed bypassing immunogenicity issues, standardization and cost-
effectiveness issues by relying on both a novel cell source and a new decellularization protocol. As a 
final validation, the regenerative potential of ECM-coated constructs has to be evaluated in order to 
clearly demonstrate the superior potential of these implants. This is currently being performed using 
a critical sized cranial defect model, in nude rat animal. This may lead to the development of an 
alternative bone repair treatment as compared to current strategies based on drug-delivery systems, 
the use of autografts/decellularized native bone and BMPs delivery. 
 
…beyond the bone 
Through the generation and validation of innovative tools, this work offers a novel protocol for 
tissue-engineering purposes. Hence, the described method -here explored in the context of bone 
tissue engineering- could be extended to the engineering of other types of tissues, such as cartilage, 
skin or tendon.  
Importantly, the cell-survival control allows bypassing limitations typically arising from the use of 
genetically modified cells, often associated with risks of tumorigenicity. On one hand, the 
immortalization allows not being time-restricted in the manipulation and selection of transformed 
cells, as no alterations of cell’s behavior/capacity can result from the population aging. On the other 
hand, the death-device allows not being limited in the number of genetic manipulation as far as cell’s 
survival remains under control with no signs of malignancy.  
This opens large perspectives, like the full engineering of a cell line by incorporating a panel of new 
functions, from the controlled release of suitable factors to the implementation of complex tracking 
systems. Cells can then be perceived as a biological tool, which can be fine-tuned in order to behave 
as a personally designed and fully predictable entity. In this regards, this strategy displays important 
similarities with current synthetic/systemic biology approaches. Together with the constant 
evolution of molecular biology techniques, targeting the precise insertion of genetic devices at 
specific loci site to avoid both key regulatory genes breakdown and transgenes silencing, this paves 
the road to the generation of stable and safe cellular tools for regenerative medicine. 
As an applied consequence, the re-engineering of cells could be performed in order to drive the 
synthesis of decellularizable, customized (enriched or depleted) ECMs.  In fact, going even beyond 
the generation of grafts for a custom regenerative performance, the concept could also offer the 
unprecedented possibility to investigate the role of the ECM and its molecular components in tissue 
homeostasis. By preserving its integrity, ECM-enriched in specific factors but depleted of the living 
compartment could be evaluated by correlating an observed regenerative capacity with a specific 
ECM composition, as described in chapter 2. Eliminating the cellular player may allow better 
dissecting the role of the ECM and associated signals involved in regeneration or other 
instructive/maintenance processes. 
 
To conclude, the depicted thesis can be perceived as the development of a tools & protocol set 
exploited for bone repair, but also proposed as a working platform for basic research investigations. 
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